US20030215798A1 - High throughput fluorescence-based screening for novel enzymes - Google Patents

High throughput fluorescence-based screening for novel enzymes Download PDF

Info

Publication number
US20030215798A1
US20030215798A1 US08/876,276 US87627697A US2003215798A1 US 20030215798 A1 US20030215798 A1 US 20030215798A1 US 87627697 A US87627697 A US 87627697A US 2003215798 A1 US2003215798 A1 US 2003215798A1
Authority
US
United States
Prior art keywords
dna
method
cells
clones
enzyme
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US08/876,276
Inventor
Jay Short
Martin Keller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BASF Enzymes LLC
Original Assignee
BASF Enzymes LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BASF Enzymes LLC filed Critical BASF Enzymes LLC
Priority to US08/876,276 priority Critical patent/US20030215798A1/en
Priority claimed from US09/444,112 external-priority patent/US6972183B1/en
Assigned to DIVERSA CORPORATION reassignment DIVERSA CORPORATION ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: KELLER, MARTIN, SHORT, JAY M.
Priority claimed from US09/687,219 external-priority patent/US6794127B1/en
Priority claimed from US09/738,871 external-priority patent/US20010041333A1/en
Priority claimed from US09/790,321 external-priority patent/US20020048809A1/en
Priority claimed from US09/894,956 external-priority patent/US20020015997A1/en
Priority claimed from US09/975,036 external-priority patent/US20030049841A1/en
Priority claimed from US10/084,552 external-priority patent/US7019827B2/en
Priority claimed from US10/095,907 external-priority patent/US20020102598A1/en
Priority claimed from US10/145,281 external-priority patent/US20030077677A1/en
Priority claimed from US10/151,469 external-priority patent/US20030219752A1/en
Priority claimed from US10/237,246 external-priority patent/US20030013115A1/en
Priority claimed from US10/286,194 external-priority patent/US20030054543A1/en
Priority claimed from US10/506,930 external-priority patent/US20050118707A1/en
Priority claimed from US10/626,477 external-priority patent/US20050070005A1/en
Priority claimed from US10/688,057 external-priority patent/US20040241759A1/en
Publication of US20030215798A1 publication Critical patent/US20030215798A1/en
Application status is Abandoned legal-status Critical

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C40COMBINATORIAL TECHNOLOGY
    • C40BCOMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES, IN SILICO LIBRARIES
    • C40B40/00Libraries per se, e.g. arrays, mixtures
    • C40B40/02Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034Isolating an individual clone by screening libraries
    • C12N15/1037Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034Isolating an individual clone by screening libraries
    • C12N15/1055Protein x Protein interaction, e.g. two hybrid selection
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6811Selection methods for production or design of target specific oligonucleotides or binding molecules

Abstract

Disclosed is a process for identifying clones having a specified activity of interest, which process comprises (i) generating one or more expression libraries derived from nuclei acid directly isolated from the environment; and (ii) screening said libraries utilizing a fluorescence activated cell sorter to identify said clones. More particularly, this is a process for identifying clones having a specified activity of interest by (i) generating one or more expression libraries derived from nucleic acid directly or indirectly isolated from the environment; (ii) exposing said libraries to a particular substrate or substrates of interest; and (iii) screening said exposed libraries utilizing a fluorescence activated cell sorter to identify clones which react with the substrate or substrates. Also provided is a process for identifying clones having a specified activity of interest by (i) generating one or more expression libraries derived from nucleic acid directly or indirectly isolated from the environment; and (ii) screening said exposed libraries utilizing an assay requiring a binding event or the covalent modification of a target, and a fluorescence activated cell sorter to identify positive clones.

Description

    BACKGROUND OF THE INVENTION
  • The present invention relates to the discovery of new bioactive molecules, such as biocatalysts. This invention employs high throughput cell analyzing, in particular fluorescence activated cell sorting (FACS), machines in a screening system designed for the rapid discovery of a large number of these molecules. [0001]
  • There is a critical need in the chemical industry for efficient catalysts for the practical synthesis of optically pure materials; enzymes can provide the optimal solution. All classes of molecules and compounds that are utilized in both established and emerging chemical, pharmaceutical, textile, food and feed, detergent markets must meet stringent economical and environmental standards. The synthesis of polymers, pharmaceuticals, natural products and agrochemicals is often hampered by expensive processes which produce harmful byproducts and which suffer from low enantioselectivity (Faber, 1995; U.S. Tonkovich and Gerber, Dept. of Energy study, 1995). Enzymes have a number of remarkable advantages which can overcome these problems in catalysis: they act on single functional groups, they distinguish between similar functional groups on a single molecule, and they distinguish between enantiomers. Moreover, they are biodegradable and function at very low mole fractions in reaction mixtures. Because of their chemo-, regio- and stereospecificity, enzymes present a unique opportunity to optimally achieve desired selective transformations. These are often extremely difficult to duplicate chemically, especially in single-step reactions. The elimination of the need for protection groups, selectivity, the ability to carry out multi-step transformations in a single reaction vessel, along with the concomitant reduction in environmental burden, has led to the increased demand for enzymes in chemical and pharmaceutical industries (Faber, 1995). Enzyme-based processes have been gradually replacing many conventional chemical-based methods (Wrotnowski, 1997). A current limitation to more widespread industrial use is primarily due to the relatively small number of commercially available enzymes. Only ˜300 enzymes (excluding DNA modifying enzymes) are at present commercially available from the >3000 non DNA-modifying enzyme activities thus far described. [0002]
  • The use of enzymes for technological applications also may require performance under demanding industrial conditions. This includes activities in environments or on substrates for which the currently known arsenal of enzymes was not evolutionarily selected. Enzymes have evolved by selective pressure to perform very specific biological functions within the milieu of a living organism, under conditions of mild temperature, pH and salt concentration. For the most part, the non-DNA modifying enzyme activities thus far described (Enzyme Nomenclature, 1992) have been isolated from mesophilic organisms, which represent a very small fraction of the available phylogenetic diversity (Amann et al., 1995). The dynamic field of biocatalysis takes on a new dimension with the help of enzymes isolated from microorganisms that thrive in extreme environments. Such enzymes must function at temperatures above 100° C. in terrestrial hot springs and deep sea thermal vents, at temperatures below 0° C. in arctic waters, in the saturated salt environment of the Dead Sea, at pH values around 0 in coal deposits and geothermal sulfur-rich springs, or at pH values greater than 11 in sewage sludge (Adams and Kelly, 1995). Enzymes obtained from these extremophilic organisms open a new field in biocatalysis. [0003]
  • For example, several esterases and lipases cloned and expressed from extremophilic organisms are remarkably robust, showing high activity throughout a wide range of temperatures and pHs. The fingerprints of five of these esterases show a diverse substrate spectrum, in addition to differences in the optimum reaction temperature. As seen in FIG. 1, esterase #5 recognizes only short chain substrates while #2 only acts on long chain substrates in addition to a huge difference in the optimal reaction temperature. These results suggest that more diverse enzymes fulfilling the need for new biocatalysts can be found by screening biodiversity. Substrates upon which enzymes act are herein defined as bioactive substrates. [0004]
  • Furthermore, virtually all of the enzymes known so far have come from cultured organisms, mostly bacteria and more recently archaea (Enzyme Nomenclature, 1992). Traditional enzyme discovery programs rely solely on cultured microorganisms for their screening programs and are thus only accessing a small fraction of natural diversity. Several recent studies have estimated that only a small percentage, conservatively less than 1%, of organisms present in the natural environment have been cultured (see Table I, Amann et al., 1995, Barns et. al 1994, Torvsik, 1990). For example, Norman Pace's laboratory recently reported intensive untapped diversity in water and sediment samples from the “Obsidian Pool” in Yellowstone National Park, a spring which has been studied since the early 1960's by microbiologists (Barns, 1994). Amplification and cloning of 16S rRNA encoding sequences revealed mostly unique sequences with little or no representation of the organisms which had previously been cultured from this pool. This suggests substantial diversity of archaea with so far unknown morphological, physiological and biochemical features which may be useful in industrial processes. David Ward's laboratory in Bozmen, Montana has performed similar studies on the cyanobacterial mat of Octopus Spring in Yellowstone Park and came to the same conclusion, namely, tremendous uncultured diversity exists (Bateson et al., 1989). Giovannoni et al. (1990) reported similar results using bacterioplankton collected in the Sargasso Sea while Torsvik et al. (1990) have shown by DNA reassociation kinetics that there is considerable diversity in soil samples. Hence, this vast majority of microorganisms represents an untapped resource for the discovery of novel biocatalysts. In order to access this potential catalytic diversity, recombinant screening approaches are required. [0005]
  • The discovery of novel bioactive molecules other than enzymes is also afforded by the present invention. For instance, antibiotics, antivirals, antitumor agents and regulatory proteins can be discovered utilizing the present invention. [0006]
  • Bacteria and many eukaryotes have a coordinated mechanism for regulating genes whose products are involved in related processes. The genes are clustered, in structures referred to as “gene clusters,” on a single chromosome and are transcribed together under the control of a single regulatory sequence, including a single promoter which initiates transcription of the entire cluster. The gene cluster, the promoter, and additional sequences that function in regulation altogether are referred to as an “operon” and can include up to 20 or more genes, usually from 2 to 6 genes. Thus, a gene cluster is a group of adjacent genes that are either identical or related, usually as to their function. [0007]
  • Some gene families consist of one or more identical members. Clustering is a prerequisite for maintaining identity between genes, although clustered genes are not necessarily identical. Gene clusters range from extremes where a duplication is generated of adjacent related genes to cases where hundreds of identical genes lie in a tandem array. Sometimes no significance is discernable in a repetition of a particular gene. A principal example of this is the expressed duplicate insulin genes in some species, whereas a single insulin gene is adequate in other mammalian species. [0008]
  • It is important to further research gene clusters and the extent to which the full length of the cluster is necessary for the expression of the proteins resulting therefrom. Gene clusters undergo continual reorganization and, thus, the ability to create heterogeneous libraries of gene clusters from, for example, bacterial or other prokaryote sources is valuable in determining sources of novel proteins, particularly including enzymes such as, for example, the polyketide synthases that are responsible for the synthesis of polyketides having a vast array of useful activities. As indicated, other types of proteins that are the product(s) of gene clusters are also contemplated, including, for example, antibiotics, antivirals, antitumor agents and regulatory proteins, such as insulin. [0009]
  • Polyketides are molecules which are an extremely rich source of bioactivities, including antibiotics (such as tetracyclines and erythromycin), anti-cancer agents (daunomycin), immunosuppressants (FK506 and rapamycin), and veterinary products (monensin). Many polyketides (produced by polyketide synthases) are valuable as therapeutic agents. Polyketide synthases are multifunctional enzymes that catalyze the biosynthesis of a huge variety of carbon chains differing in length and patterns of functionality and cyclization. Polyketide synthase genes fall into gene clusters and at least one type (designated type I) of polyketide synthases have large size genes and encoded enzymes, complicating genetic manipulation and in vitro studies of these genes/proteins. The method(s) of the present invention facilitate the rapid discovery of these gene clusters in gene expression libraries. [0010]
  • The present invention combines a culture-independent approach to directly clone genes encoding novel bioactivities from environmental samples with an extremely high throughput screening system designed for the rapid discovery of new biomolecules. [0011]
  • The strategy begins with the construction of gene libraries which represent the genome(s) of microorganisms archived in cloning vectors that can be propagated in [0012] E. coli or other suitable prokaryotic hosts. Preferably, “environmental libraries” which represent the collective genomes of naturally occurring microorganisms are generated. In this case, because the cloned DNA is extracted directly from environmental samples, the libraries are not limited to the small fraction of prokaryotes that can be grown in pure culture. In addition, “normalization” can be performed on the environmental nucleic acid as one approach to more equally represent the DNA from all of the species present in the original sample. Normalization techniques can dramatically increase the efficiency of discovery from genomes which may represent minor constituents of the environmental sample. Normalization is preferable since at least one study has demonstrated that an organism of interest can be underrepresented by five orders of magnitude compared to the dominant species (Stetter, pers. comm.).
  • When attempting to identify genes encoding bioactivities of interest from complex environmental expression libraries, the rate limiting steps in discovery occur at the both DNA cloning level and at the screening level. Screening of complex environmental libraries which contain, for example, 100's of different organisms requires the analysis of several million clones to cover this genomic diversity. An extremely high-throughput screening method has been developed to handle the enormous numbers of clones present in these libraries. [0013]
  • In traditional flow cytometry, it is common to analyze very large numbers of eukaryotic cells in a short period of time. Newly developed flow cytometers can analyze and sort up to 20,000 cells per second. In a typical flow cytometer, individual particles pass through an illumination zone and appropriate detectors, gated electronically, measure the magnitude of a pulse representing the extent of light scattered. The magnitude of these pulses are sorted electronically into “bins” or “channels,” permitting the display of histograms of the number of cells possessing a certain quantitative property versus the channel number (Davey and Kell, 1996). It was recognized early on that the data accruing from flow cytometric measurements could be analyzed (electronically) rapidly enough that electronic cell-sorting procedures could be used to sort cells with desired properties into separate “buckets,” a procedure usually known as fluorescence-activated cell sorting (Davey and Kell, 1996). [0014]
  • Fluorescence-activated cell sorting has been primarily used in studies of human and animal cell lines and the control of cell culture processes. Fluorophore labeling of cells and measurement of the fluorescence can give quantitative data about specific target molecules or subcellular components and their distribution in the cell population. Flow cytometry can quantitate virtually any cell-associated property or cell organelle for which there is a fluorescent probe (or natural fluorescence). The parameters which can be measured have previously been of particular interest in animal cell culture. [0015]
  • Flow cytometry has also been used in cloning and selection of variants from existing cell clones. This selection, however, has required stains that diffuse through cells passively, rapidly and irreversibly, with no toxic effects or other influences on metabolic or physiological processes. Since, typically, flow sorting has been used to study animal cell culture performance, physiological state of cells, and the cell cycle, one goal of cell sorting has been to keep the cells viable during and after sorting. [0016]
  • There currently are no reports in the literature of screening and discovery of recombinant enzymes in [0017] E. coli expression libraries by fluorescence activated cell sorting of single cells. Furthermore there are no reports of recovering DNA encoding bioactivities screened by expression screening in E. coli using a FACS machine. The present invention provides these methods to allow the extremely rapid screening of viable or non-viable cells to recover desirable activities and the nucleic acid encoding those activities.
  • A limited number of papers describing various applications of flow cytometry in the field of microbiology and sorting of fluorescence activated microorganisms have, however, been published (Davey and Kell, 1996). Fluorescence and other forms of staining have been employed for microbial discrimination and identification, and in the analysis of the interaction of drugs and antibiotics with microbial cells. Flow cytometry has been used in aquatic biology, where autofluorescence of photosynthetic pigments are used in the identification of algae or DNA stains are used to quantify and count marine populations (Davey and Kell, 1996). Thus, Diaper and Edwards used flow cytometry to detect viable bacteria after staining with a range of fluorogenic esters including fluorescein diacetate (FDA) derivatives and CemChrome B, a proprietary stain sold commercially for the detection of viable bacteria in suspension (Diaper and Edwards, 1994). Labeled antibodies and oligonucleotide probes have also been used for these purposes. [0018]
  • Papers have also been published describing the application of flow cytometry to the detection of native and recombinant enzymatic activities in eukaryotes. Betz et al. studied native (non-recombinant) lipase production by the eukaryote, [0019] Rhizopus arrhizus with flow cytometry. They found that spore suspensions of the mold were heterogeneous as judged by light-scattering data obtained with excitation at 633 nm, and they sorted clones of the subpopulations into the wells of microtiter plates. After germination and growth, lipase production was automatically assayed (turbidimetrically) in the microtiter plates, and a representative set of the most active were reisolated, cultured, and assayed conventionally (Betz et al., 1984).
  • Scrienc et al. have reported a flow cytometric method for detecting cloned -galactosidase activity in the eukaryotic organism, [0020] S. cerevisiae. The ability of flow cytometry to make measurements on single cells means that individual cells with high levels of expression (e.g., due to gene amplification or higher plasmid copy number) could be detected. In the method reported, a non-fluorescent compound β-naphthol-β-galactopyranoside) is cleaved by β-galactosidase and the liberated naphthol is trapped to form an insoluble fluorescent product. The insolubility of the fluorescent product is of great importance here to prevent its diffusion from the cell. Such diffusion would not only lead to an underestimation of β-galactosidase activity in highly active cells but could also lead to an overestimation of enzyme activity in inactive cells or those with low activity, as they may take up the leaked fluorescent compound, thus reducing the apparent heterogeneity of the population.
  • One group has described the use of a FACS machine in an assay detecting fusion proteins expressed from a specialized transducing bacteriophage in the prokaryote [0021] Bacillus subtilis (Chung, et. al., J. of Bacteriology, April 1994, p. 1977-1984; Chung, et. al., Biotechnology and Bioengineering, Vol. 47, pp. 234-242 (1995)). This group monitored the expression of a lacZ gene (encodes b-galactosidase) fused to the sporulation loci in subtilis (spo). The technique used to monitor b-galactosidase expression from spo-lacZ fusions in single cells involved taking samples from a sporulating culture, staining them with a commercially available fluorogenic substrate for b-galactosidase called C8-FDG, and quantitatively analyzing fluorescence in single cells by flow cytometry. In this study, the flow cytometer was used as a detector to screen for the presence of the spo gene during the development of the cells. The device was not used to screen and recover positive cells from a gene expression library or nucleic acid for the purpose of discovery.
  • Another group has utilized flow cytometry to distinguish between the developmental stages of the delta-proteobacteria [0022] Myxococcus xanthus (F. Russo-Marie, et. al., PNAS, Vol. 90, pp. 8194-8198, September 1993). As in the previously described study, this study employed the capabilities of the FACS machine to detect and distinguish genotypically identical cells in different development regulatory states. The screening of an enzymatic activity was used in this study as an indirect measure of developmental changes.
  • The lacZ gene from [0023] E. coli is often used as a reporter gene in studies of gene expression regulation, such as those to determine promoter efficiency, the effects of trans-acting factors, and the effects of other regulatory elements in bacterial, yeast, and animal cells. Using a chromogenic substrate, such as ONPG (o-nitrophenyl-(-D-galactopyranoside), one can measure expression of β-galactosidase in cell cultures; but it is not possible to monitor expression in individual cells and to analyze the heterogeneity of expression in cell populations. The use of fluorogenic substrates, however, makes it possible to determine β-galactosidase activity in a large number of individual cells by means of flow cytometry. This type of determination can be more informative with regard to the physiology of the cells, since gene expression can be correlated with the stage in the mitotic cycle or the viability under certain conditions. In 1994, Plovins, A., et al reported the use of fluorescein-Di-β-D-galactopyranoside (FDG) and C12-FDG as substrates for β-galactosidase detection in animal, bacterial, and yeast cells. This study compared the two molecules as substrates for β-galactosidase, and concluded that FDG is a better substrate for β-galactosidase detection by flow cytometry in bacterial cells. The screening performed in this study was for the comparison of the two substrates. The detection capabilities of a FACS machine were employed to perform the study on viable bacterial cells.
  • Cells with chromogenic or fluorogenic substrates yield colored and fluorescent products, respectively. Previously, it had been thought that the flow cytometry-fluorescence-activated cell sorter approaches could be of benefit only for the analysis of cells that contain intracellularly, or are normally physically associated with, the enzymatic activity of small molecule of interest. On this basis, one could only use fluorogenic reagents which could penetrate the cell and which are thus potentially cytotoxic. To avoid clumping of heterogeneous cells, it is desirable in flow cytometry to analyze only individual cells, and this could limit the sensitivity and therefore the concentration of target molecules that can be sensed. Weaver and his colleagues at MIT and others have developed the use of gel microdroplets containing (physically) single cells which can take up nutrients, secret products, and grow to form colonies. The diffusional properties of gel microdroplets may be made such that sufficient extracellular product remains associated with each individual gel microdroplet, so as to permit flow cytometric analysis and cell sorting on the basis of concentration of secreted molecule within each microdroplet. Beads have also been used to isolate mutants growing at different rates, and to analyze antibody secretion by hybridoma cells and the nutrient sensitivity of hybridoma cells. The gel microdroplet method has also been applied to the rapid analysis of mycobacterial growth and its inhibition by antibiotics. [0024]
  • The gel microdroplet technology has had significance in amplifying the signals available in flow cytometric analysis, and in permitting the screening of microbial strains in strain improvement programs for biotechnology. Wittrup et. al.(Biotechnolo. Bioeng. (1993) 42:351-356) developed a microencapsulation selection method which allows the rapid and quantitative screening of >10[0025] 6 yeast cells for enhanced secretion of Aspergillus awamori glucoamylase. The method provides a 400-fold single-pass enrichment for high-secretion mutants.
  • Gel microdroplet or other related technologies can be used in the present invention to localize as well as amplify signals in the high throughput screening of recombinant libraries. Cell viability during the screening is not an issue or concern since nucleic acid can be recovered from the microdroplet. [0026]
  • Different types of encapsulation strategies and compounds or polymers can be used with the present invention. For instance, high temperature agaroses can be employed for making microdroplets stable at high temperatures, allowing stable encapsulation of cells subsequent to heat kill steps utilized to remove all background activities when screening for thermostable bioactivities. [0027]
  • There are several hurdles which must be overcome when attempting to detect and sort [0028] E. coli expressing recombinant enzymes, and recover encoding nucleic acids. FACS systems have typically been based on eukaryotic separations and have not been refined to accurately sort single E. coli cells; the low forward and sideward scatter of small particles like E. coli, reduces the ability of accurate sorting; enzyme substrates typically used in automated screening approaches, such as umbelifferyl based substrates, diffuse out of E. coli at rates which interfere with quantitation. Furthermore, recovery of very small amounts of DNA from sorted organisms can be problematic. The present invention addresses and overcomes these hurdles and offers a novel screening approach.
  • SUMMARY OF THE INVENTION
  • The present invention adapts traditional eukaryotic flow cytometry cell sorting systems to high throughput screening for expression clones in prokaryotes. In the present invention, expression libraries derived from DNA, primarily DNA directly isolated from the environment, are screened very rapidly for bioactivities of interest utilizing fluorescense activated cell sorting. These libraries can contain greater than 10[0029] 8 members and can represent single organisms or can represent the genomes of over 100 different microorganisms, species or subspecies.
  • This invention differs from fluorescense activated cell sorting, as normally performed, in several aspects. Previously, FACS machines have been employed in the studies focused on the analyses of eukaryotic and prokaryotic cell lines and cell culture processes. FACS has also been utilized to monitor production of foreign proteins in both eukaryotes and prokaryotes to study, for example, differential gene expression, etc. The detection and counting capabilities of the FACS system have been applied in these examples. However, FACS has never previously been employed in a discovery process to screen for and recover bioactivities in prokaryotes. Furthermore, the present invention does not require cells to survive, as do previously described technologies, since the desired nucleic acid (recombinant clones) can be obtained from alive or dead cells. The cells only need to be viable long enough to produce the compound to be detected, and can thereafter be either viable or non-viable cells so long as the expressed biomolecule remains active. The present invention also solves problems that would have been associated with detection and sorting of [0030] E. coli expressing recombinant enzymes, and recovering encoding nucleic acids. Additionally, the present invention includes within its embodiments any apparatus capable of detecting flourescent wavelengths associated with biological material, such apparatii are defined herein as fluorescent analyzers (one example of which is a FACS).
  • The use of a culture-independent approach to directly clone genes encoding novel enzymes from environmental samples allows one to access untapped resources of biodiversity. The approach is based on the construction of “environmental libraries” which represent the collective genomes of naturally occurring organisms archived in cloning vectors that can be propagated in suitable prokaryotic hosts. Because the cloned DNA is initially extracted directly from environmental samples, the libraries are not limited to the small fraction of prokaryotes that can be grown in pure culture. Additionally, a normalization of the environmental DNA present in these samples could allow more equal representation of the DNA from all of the species present in the original sample. This can dramatically increase the efficiency of finding interesting genes from minor constituents of the sample which may be under-represented by several orders of magnitude compared to the dominant species. [0031]
  • In the evaluation of complex environmental expression libraries, a rate limiting step previously occurred at the level of discovery of bioactivities. The present invention allows the rapid screening of complex environmental expression libraries, containing, for example, thousands of different organisms. The analysis of a complex sample of this size requires one to screen several million clones to cover this genomic biodiversity. The invention represents an extremely high-throughput screening method which allows one to assess this enormous number of clones. The method disclosed allows the screening of at least about 36 million clones per hour for a desired biological activity. This allows the thorough screening of environmental libraries for clones expressing novel biomolecules. [0032]
  • In the present invention, for example, gene libraries generated from one or more uncultivated microorganisms are screened for an activity of interest. Expression gene libraries are generated, clones are either exposed to the substrate or substrate(s) of interest, hybridized to a probe of interest, or bound to a detectable ligand and positive clones are identified and isolated via fluorescence activated cell sorting. Cells can be viable or non-viable during the process or at the end of the process, as nucleic acid encoding a positive activity can be isolated and cloned utilizing techniques well known in the art. [0033]
  • Accordingly, in one aspect, the present invention provides a process for identifying clones having a specified activity of interest, which process comprises (i) generating one or more expression libraries derived from nucleic acid directly isolated from the environment; and (ii) screening said libraries utilizing a high throughput cell analyzer, preferably a fluorescence activated cell sorter, to identify said clones. [0034]
  • More particularly, the invention provides a process for identifying clones having a specified activity of interest by (i) generating one or more expression libraries made to contain nucleic acid directly or indirectly isolated from the environment; (ii) exposing said libraries to a particular substrate or substrates of interest; and (iii) screening said exposed libraries utilizing a high throughput cell analyzer, preferably a fluorescence activated cell sorter, to identify clones which react with the substrate or substrates. [0035]
  • In another aspect, the invention also provides a process for identifying clones having a specified activity of interest by (i) generating one or more expression libraries derived from nucleic acid directly or indirectly isolated from the environment; and (ii) screening said exposed libraries utilizing an assay requiring a binding event or the covalent modification of a target, and a high throughput cell analyzer, preferably a fluorescence activated cell sorter, to identify positive clones.[0036]
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1 illustrates the substrate spectrum fingerprints and optimum reaction temperatures of five of novel esterases showing the diversity in these enzymes. EST# indicates the different enzyme; the temperatures indicate the optimal growth temperatures for the organisms from which the esterases were isolated; “E” indicates the relative activity of each esterase enzyme on each of the given substrates indicated (Hepanoate being the reference). [0037]
  • FIG. 2 illustrates the cloning of DNA fragments prepared by random cleavage of target DNA to generate a representative library as described in Example 1. [0038]
  • FIG. 3. In order to assess the total number of clones to be tested (e.g. the number of genome equivalents) a statistical analysis was performed. Assuming that mechanical shearing and gradient purification results in normal distribution of DNA fragment sizes with a mean of 4.5 kbp and variance of 1 kbp, the fraction represented of all possible 1 kbp sequences in a 1.8 Mbp genome is plotted in FIG. 3 as a function of increasing genome equivalents. [0039]
  • FIG. 4 illustrates the protocol used in the cell sorting method of the invention to screen for recombinant enzymes, in this case using a (library excised into [0040] E. coli. The expression clones of interest are isolated by sorting. The procedure is described in detail in Examples 1, 3 and 4.
  • FIG. 5 shows β-galactosidase clones stained with three different substrates: fluorescein-di-β-D-galactopyranoside (FDG), C12-fluorescein-di-β-D-galactopyranoside (C12FDG), chloromethyl-fluorescein-di-β-D-galactopyranoside (CMFDG). [0041] E. coli expressing β-galactosidase from Sulfulobus sulfotaricus species was grown overnight. Cells were centrifuged and substrate was loaded with deionized water. After five (5) minutes cells were centrifuged and transferred into HEPES buffer and heated to 70° C for thirty (30) minutes. Cells were spotted onto a slide and exposed to UV light. This illustrates the results of the experiments described in Example 3.
  • FIG. 6 shows a microtiter plate where [0042] E. coli cells sorted in accordance with the invention are dispensed, one cell per well and grown up as clones which are then stained with fluorescein-di-β-D-galactopyranoside (FDG) (10 mM). This illustrates the results of the experiments described in Example 5.
  • FIG. 7 shows the principle type of fluorescence enzyme assay of deacylation. [0043]
  • FIG. 8 shows staining of β-galactosidase clones from the hyperthermophilic archaeon [0044] Sulfolobus solfataricus expressed in E. coli using C12-FDG as enzyme substrate.
  • FIG. 9 shows the synthesis of 5-dodecanoyl-aminofluorescein-di-dodecanoic acid. [0045]
  • FIG. 10 shows Rhodamine protease substrate. [0046]
  • FIG. 11 shows a compound and process that can be used in the detection of monooxygenases. [0047]
  • FIG. 12 is a schematic illustration of combinatorial enzyme development using directed evolution. [0048]
  • FIG. 13 is a schematic illustration showing bypassing barriers to directed evolution.[0049]
  • DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS
  • The method of the present invention begins with the construction of gene libraries which represent the collective genomes of naturally occurring organisms archived in cloning vectors that can be propagated in suitable prokaryotic hosts. [0050]
  • The microorganisms from which the libraries may be prepared include prokaryotic microorganisms, such as Eubacteria and Archaebacteria, and lower eukaryotic microorganisms such as fungi, some algae and protozoa. Libraries may be produced from environmental samples in which case DNA may be recovered without culturing of an organism or the DNA may be recovered from a cultured organism. Such microorganisms may be extremophiles, such as hyperthermophiles, psychrophiles, psychrotrophs, halophiles, alkalophiles, acidophiles, etc. [0051]
  • Sources of microorganism DNA as a starting material library from which target DNA is obtained are particularly contemplated to include environmental samples, such as microbial samples obtained from Arctic and Antarctic ice, water or permafrost sources, materials of volcanic origin, materials from soil or plant sources in tropical areas, etc. Thus, for example, genomic DNA may be recovered from either a culturable or non-culturable organism and employed to produce an appropriate recombinant expression library for subsequent determination of enzyme or other biological activity. Prokaryotic expression libraries created from such starting material which includes DNA from more than one species are defined herein as multispecific libraries. [0052]
  • In one embodiment, viable or non-viable cells isolated from the environment are, prior to the isolation of nucleic acid for generation of the expression gene library, FACS sorted to separate prokaryotic cells from the sample based on, for instance, DNA or AT/GC content of the cells. Various dyes or stains well known in the art, for example those described in “Practical Flow Cytometry”, 1995 Wiley-Liss, Inc., Howard M. Shapiro, M.D., are used to intercalate or associate with nucleic acid of cells, and cells are separated on the FACS based on relative DNA content or AT/GC DNA content in the cells. Other criteria can also be used to separate prokaryotic cells from the sample, as well. DNA is then isolated from the cells and used for the generation of expression gene libraries, which are then screened using the FACS for activities of interest. [0053]
  • Alternatively, the nucleic acid is isolated directly from the environment and is, prior to generation of the gene library, sorted based on DNA or AT/GC content. DNA isolated directly from the environment, is used intact, randomly sheared or digested to general fragmented DNA. The DNA is then bound to an intercalating agent as described above, and separated on the analyzer based on relative base content to isolate DNA of interest. Sorted DNA is then used for the generation of gene libraries, which are then screened using the analyzer for activities of interest. [0054]
  • The present invention can further optimize methods for isolation of activities of interest from a variety of sources, including consortias of microorganisms, primary enrichments, and environmental “uncultivated” samples, to make libraries which have been “normalized” in their representation of the genome populations in the original samples. and to screen these libraries for enzyme and other bioactivities. Libraries with equivalent representation of genomes from microbes that can differ vastly in abundance in natural populations are generated and screened. This “normalization” approach reduces the redundancy of clones from abundant species and increases the representation of clones from rare species. These normalized libraries allow for greater screening efficiency resulting in the identification of cells encoding novel biological catalysts. [0055]
  • One embodiment for forming a normalized library from an environmental sample begins with the isolation of nucleic acid from the sample. This nucleic acid can then be fractionated prior to normalization to increase the chances of cloning DNA from minor species from the pool of organisms sampled. DNA can be fractionated using a density centrifugation technique, such as a cesium-chloride gradient. When an intercalating agent, such as bis-benzimide is employed to change the buoyant density of the nucleic acid, gradients will fractionate the DNA based on relative base content. Nucleic acid from multiple organisms can be separated in this manner, and this technique can be used to fractionate complex mixtures of genomes. This can be of particular value when working with complex environmental samples. Alternatively, the DNA does not have to be fractionated prior to normalization. Samples are recovered from the fractionated DNA, and the strands of nucleic acid are then melted and allowed to selectively reanneal under fixed conditions (C[0056] ot driven hybridization). When a mixture of nucleic acid fragments is melted and allowed to reanneal under stringent conditions, the common sequences find their complementary strands faster than the rare sequences. After an optional single-stranded nucleic acid isolation step, single-stranded nucleic acid representing an enrichment of rare sequences is amplified using techniques well known in the art, such as a polymerase chain reaction (Barnes, 1994), and used to generate gene libraries. This procedure leads to the amplification of rare or low abundance nucleic acid molecules, which are then used to generate a gene library which can be screened for a desired bioactivity. While DNA will be recovered, the identification of the organism(s) originally containing the DNA may be lost. This method offers the ability to recover DNA from “unclonable” sources.
  • Hence, one embodiment for forming a normalized library from environmental sample(s) is by (a) isolating nucleic acid from the environmental sample(s); (b) optionally fractionating the nucleic acid and recovering desired fractions; (c) normalizing the representation of the DNA within the population so as to form a normalized expression library from the DNA of the environmental sample(s). The “normalization” process is described and exemplified in detail in co-pending, commonly assigned U.S. Ser. No. 08/665,565, filed Jun. 18, 1996. [0057]
  • The preparation of DNA from the sample is an important step in the generation of normalized or non-normalized DNA libraries from environmental samples composed of uncultivated organisms, or for the generation of libraries from cultivated organisms. DNA can be isolated from samples using various techniques well known in the art (Nucleic Acids in the Environment Methods & Applications, J. T. Trevors, D. D. van Elsas, Springer Laboratory, 1995). Preferably, DNA obtained will be of large size and free of enzyme inhibitors or other contaminants. DNA can be isolated directly from an environmental sample (direct lysis), or cells may be harvested from the sample prior to DNA recovery (cell separation) . Direct lysis procedures have several advantages over protocols based on cell separation. The direct lysis technique provides more DNA with a generally higher representation of the microbial community, however, it is sometimes smaller in size and more likely to contain enzyme inhibitors than DNA recovered using the cell separation technique. Very useful direct lysis techniques have been described which provide DNA of high molecular weight and high purity (Barns, 1994; Holben, 1994). If inhibitors are present, there are several protocols which utilize cell isolation which can be employed (Holben, 1994). Additionally, a fractionation technique, such as the bis-benzimide separation (cesium chloride isolation) described, can be used to enhance the purity of the DNA. [0058]
  • Isolation of total genomic DNA from extreme environmental samples varies depending on the source and quantity of material. Uncontaminated, good quality (>20 kbp) DNA is required for the construction of a representative library. A successful general DNA isolation protocol is the standard cetyl-trimethyl-ammonium-bromide (CTAB) precipitation technique. A biomass pellet is lysed and proteins digested by the nonspecific protease, proteinase K, in the presence of the detergent SDS. At elevated temperatures and high salt concentrations, CTAB forms insoluble complexes with denatured protein, polysaccharides and cell debris. Chloroform extractions are performed until the white interface containing the CTAB complexes is reduced substantially. The nucleic acids in the supernatant are precipitated with isopropanol and resuspended in TE buffer. [0059]
  • For cells which are recalcitrant to lysis, a combination of chemical and mechanical methods with cocktails of various cell-lysing enzymes may be employed. Isolated nucleic acid may then further be purified using small cesium gradients. [0060]
  • Gene libraries can be generated by inserting the DNA isolated or derived from a sample into a vector or a plasmid. Such vectors or plasmids are preferably those containing expression regulatory sequences, including promoters, enhancers and the like. Such polynucleotides can be part of a vector and/or a composition and still be isolated, in that such vector or composition is not part of its natural environment. Particularly preferred phage or plasmids and methods for introduction and packaging into them are described herein. [0061]
  • The following outlines a general procedure for producing libraries from both culturable and non-culturable organisms: [0062]
  • Obtain Biomass [0063]
  • DNA Isolation (various methods) [0064]
  • Shear DNA (for example, with a 25 gauge needle) [0065]
  • Blunt DNA [0066]
  • Methylate DNA [0067]
  • Ligate to linkers [0068]
  • Cut back linkers [0069]
  • Size Fractionate (for example, use a Sucrose Gradient) [0070]
  • Ligate to lambda expression vector [0071]
  • Package (in vitro lambda packaging extract) [0072]
  • Plate on [0073] E. coli host and amplify
  • As detailed in FIG. 1, cloning DNA fragments prepared by random cleavage of the target DNA generates a representative library. DNA dissolved in TE buffer is vigorously passed through a 25 gauge double-hubbed needle until the sheared fragments are in the desired size range. The DNA ends are “polished” or blunted with Mung Bean Nuclease, and EcoRI restriction sites in the target DNA are protected with EcoRI Methylase. EcoRI linkers (GGAATTCC) are ligated to the blunted/protected DNA using a very high molar ratio of linkers to target DNA. This lowers the probability of two DNA molecules ligating together to create a chimeric clone. The linkers are cut back with EcoRI restriction endonuclease and the DNA is size fractionated. The removal of sub-optimal DNA fragments and the small linkers is critical because ligation to the vector will result in recombinant molecules that are unpackageable, or the construction of a library containing only linkers as inserts. Sucrose gradient fractionation is used since it is extremely easy, rapid and reliable. Although the sucrose gradients do not provide the resolution of agarose gel isolations, they do produce DNA that is relatively free of inhibiting contaminants. The prepared target DNA is ligated to the lambda vector, packaged using in vitro packaging extracts and grown on the appropriate [0074] E. coli.
  • As representative examples of expression vectors which may be used there may be mentioned viral particles, baculovirus, phage, plasmids, phagemids, cosmids, fosmids, bacterial artificial chromosomes, viral DNA (e.g. vaccinia, adenovirus, foul pox virus, pseudorabies and derivatives of SV40), P1-based artificial chromosomes, yeast plasmids, yeast artificial chromosomes, and any other vectors specific for specific hosts of interest (such as bacillus, aspergillus, yeast, etc.) Thus, for example, the DNA may be included in any one of a variety of expression vectors for expressing a polypeptide. Such vectors include chromosomal, nonchromosomal and synthetic DNA sequences. Large numbers of suitable vectors are known to those of skill in the art, and are commercially available. The following vectors are provided by way of example; Bacterial: pQE vectors (Qiagen), pBluescript plasmids, pNH vectors, (ZAP vectors (Stratagene); ptrc99a, pKK223-3, pDR540, pRIT2T (Pharmacia); Eukaryotic: pXT1, pSG5 (Stratagene), pSVK3, PBPV, PMSG, pSVLSV40 (Pharmacia). However, any other plasmid or other vector may be used as long as they are replicable and viable in the host. [0075]
  • Another type of vector for use in the present invention contains an f-factor origin replication. The f-factor (or fertility factor) in [0076] E. coli is a plasmid which effects high frequency transfer of itself during conjugation and less frequent transfer of the bacterial chromosome itself. A particularly preferred embodiment is to use cloning vectors, referred to as “fosmids” or bacterial artificial chromosome (BAC) vectors. These are derived from E. coli f-factor which is able to stably integrate large segments of genomic DNA. When integrated with DNA from a mixed uncultured environmental sample, this makes it possible to achieve large genomic fragments in the form of a stable “environmental DNA library.”
  • The DNA sequence in the expression vector is operatively linked to an appropriate expression control sequence(s) (promoter) to direct RNA synthesis. Particular named bacterial promoters include lacI, lacZ, T3, T7, gpt, lambda P[0077] R, PL and trp. Eukaryotic promoters include CMV immediate early, HSV thymidine kinase, early and late SV40, LTRs from retrovirus, and mouse metallothionein-I. Selection of the appropriate vector and promoter is well within the level of ordinary skill in the art. The expression vector also contains a ribosome binding site for translation initiation and a transcription terminator. The vector may also include appropriate sequences for amplifying expression. Promoter regions can be selected from any desired gene using CAT (chloramphenicol transferase) vectors or other vectors with selectable markers.
  • In addition, the expression vectors preferably contain one or more selectable marker genes to provide a phenotypic trait for selection of transformed host cells such as dihydrofolate reductase or neomycin resistance for eukaryotic cell culture, or such as tetracycline or ampicillin resistance in [0078] E. coli.
  • Generally, recombinant expression vectors will include origins of replication and selectable markers permitting transformation of the host cell, e.g., the ampicillin resistance gene of [0079] E. coli and S. cerevisiae TRP1 gene, and a promoter derived from a highly-expressed gene to direct transcription of a downstream structural sequence. Such promoters can be derived from operons encoding glycolytic enzymes such as 3-phosphoglycerate kinase (PGK), (-factor, acid phosphatase, or heat shock proteins, among others. The heterologous structural sequence is assembled in appropriate phase with translation initiation and termination sequences, and preferably, a leader sequence capable of directing secretion of translated protein into the periplasmic space or extracellular medium.
  • The cloning strategy permits expression via both vector driven and endogenous promoters; vector promotion may be important with expression of genes whose endogenous promoter will not function in [0080] E. coli.
  • The DNA derived from a microorganism(s) may be inserted into the vector by a variety of procedures. In general, the DNA sequence is inserted into an appropriate restriction endonuclease site(s) by procedures known in the art. Such procedures and others are deemed to be within the scope of those skilled in the art. [0081]
  • The DNA selected and isolated as hereinabove described is introduced into a suitable host to prepare a library which is screened for the desired enzyme activity. The selected DNA is preferably already in a vector which includes appropriate control sequences whereby selected DNA which encodes for an enzyme may be expressed, for detection of the desired activity. The host cell is a prokaryotic cell, such as a bacterial cell. Particularly preferred host cells are [0082] E. coli. Introduction of the construct into the host cell can be effected by calcium phosphate transfection, DEAE-Dextran mediated transfection, or electroporation (Davis, L., Dibner, M., Battey, I., Basic Methods in Molecular Biology, (1986)). The selection of an appropriate host is deemed to be within the scope of those skilled in the art from the teachings herein.
  • Host cells are genetically engineered (transduced or transformed or transfected) with the vectors. The engineered host cells can be cultured in conventional nutrient media modified as appropriate for activating promoters, selecting transformants or amplifying genes. The culture conditions, such as temperature, pH and the like, are those previously used with the host cell selected for expression, and will be apparent to the ordinarily skilled artisan. [0083]
  • It is also contemplated that expression libraries generated can be phage display or cell surface display libraries. Numerous techniques are published in the art for generating such libraries. [0084]
  • After the expression libraries have been generated one can include the additional step of “biopanning” such libraries prior to screening by cell sorting. The “biopanning” procedure refers to a process for identifying clones having a specified biological activity by screening for sequence homology in a library of clones prepared by (i) selectively isolating target DNA, from DNA derived from at least one microorganism, by use of at least one probe DNA comprising at least a portion of a DNA sequence encoding an biological having the specified biological activity; and (ii) transforming a host with isolated target DNA to produce a library of clones which are screened for the specified biological activity. [0085]
  • The probe DNA used for selectively isolating the target DNA of interest from the DNA derived from at least one microorganism can be a full-length coding region sequence or a partial coding region sequence of DNA for an enzyme of known activity. The original DNA library can be preferably probed using mixtures of probes comprising at least a portion of the DNA sequence encoding an enzyme having the specified enzyme activity. These probes or probe libraries are preferably single-stranded and the microbial DNA which is probed has preferably been converted into single-stranded form. The probes that are particularly suitable are those derived from DNA encoding enzymes having an activity similar or identical to the specified enzyme activity which is to be screened. [0086]
  • The probe DNA should be at least about 10 bases and preferably at least 15 bases. In one embodiment, the entire coding region may be employed as a probe. Conditions for the hybridization in which target DNA is selectively isolated by the use of at least one DNA probe will be designed to provide a hybridization stringency of at least about 50% sequence identity, more particularly a stringency providing for a sequence identity of at least about 70%. [0087]
  • Hybridization techniques for probing a microbial DNA library to isolate target DNA of potential interest are well known in the art and any of those which are described in the literature are suitable for use herein, particularly those which use a solid phase-bound, directly or indirectly bound, probe DNA for ease in separation from the remainder of the DNA derived from the microorganisms. [0088]
  • Preferably the probe DNA is “labeled” with one partner of a specific binding pair (i.e. a ligand) and the other partner of the pair is bound to a solid matrix to provide ease of separation of target from its source. The ligand and specific binding partner can be selected from, in either orientation, the following: (1) an antigen or hapten and an antibody or specific binding fragment thereof; (2) biotin or iminobiotin and avidin or streptavidin; (3) a sugar and a lectin specific therefor; (4) an enzyme and an inhibitor therefor; (5) an apoenzyme and cofactor; (6) complementary homopolymeric oligonucleotides; and (7) a hormone and a receptor therefor. The solid phase is preferably selected from: (1) a glass or polymeric surface; (2) a packed column of polymeric beads; and (3) magnetic or paramagnetic particles. [0089]
  • Further, it is optional but desirable to perform an amplification of the target DNA that has been isolated. In this embodiment the target DNA is separated from the probe DNA after isolation. It is then amplified before being used to transform hosts. The double stranded DNA selected to include as at least a portion thereof a predetermined DNA sequence can be rendered single stranded, subjected to amplification and reannealed to provide amplified numbers of selected double stranded DNA. Numerous amplification methodologies are now well known in the art. [0090]
  • The selected DNA is then used for preparing a library for screening by transforming a suitable organism. Hosts, particularly those specifically identified herein as preferred, are transformed by artificial introduction of the vectors containing the target DNA by inoculation under conditions conducive for such transformation. [0091]
  • The resultant libraries of transformed clones are then screened for clones which display activity for the enzyme of interest. [0092]
  • Having prepared a multiplicity of clones from DNA selectively isolated from an organism, such clones are screened for a specific enzyme activity and to identify the clones having the specified enzyme characteristics. [0093]
  • The screening for enzyme activity may be effected on individual expression clones or may be initially effected on a mixture of expression clones to ascertain whether or not the mixture has one or more specified enzyme activities. If the mixture has a specified enzyme activity, then the individual clones may be rescreened utilizing a FACS machine for such enzyme activity or for a more specific activity. Alternatively, encapsulation techniques such as gel microdroplets, may be employed to localize multiple clones in one location to be screened on a FACS machine for positive expressing clones within the group of clones which can then be broken out into individual clones to be screened again on a FACS machine to identify positive individual clones. Thus, for example, if a clone mixture has hydrolase activity, then the individual clones may be recovered and screened utilizing a FACS machine to determine which of such clones has hydrolase activity. [0094]
  • As described with respect to one of the above aspects, the invention provides a process for enzyme activity screening of clones containing selected DNA derived from a microorganism which process comprises: [0095]
  • screening a library for specified enzyme activity, said library including a plurality of clones, said clones having been prepared by recovering from genomic DNA of a microorganism selected DNA, which DNA is selected by hybridization to at least one DNA sequence which is all or a portion of a DNA sequence encoding an enzyme having the specified activity; and [0096]
  • transforming a host with the selected DNA to produce clones which are screened for the specified enzyme activity. [0097]
  • In one embodiment, a DNA library derived from a microorganism is subjected to a selection procedure to select therefrom DNA which hybridizes to one or more probe DNA sequences which is all or a portion of a DNA sequence encoding an enzyme having the specified enzyme activity by: [0098]
  • (a) rendering the double-stranded genomic DNA population into a single-stranded DNA population; [0099]
  • (b) contacting the single-stranded DNA population of (a) with the DNA probe bound to a ligand under conditions permissive of hybridization so as to produce a double-stranded complex of probe and members of the genomic DNA population which hybridize thereto; [0100]
  • (c) contacting the double-stranded complex of (b) with a solid phase specific binding partner for said ligand so as to produce a solid phase complex; [0101]
  • (d) separating the solid phase complex from the single-stranded DNA population of (b); [0102]
  • (e) releasing from the probe the members of the genomic population which had bound to the solid phase bound probe; [0103]
  • (f) forming double-stranded DNA from the members of the genomic population of (e); [0104]
  • (g) introducing the double-stranded DNA of (f) into a suitable host to form a library containing a plurality of clones containing the selected DNA; and [0105]
  • (h) screening the library for the specified enzyme activity. [0106]
  • In another aspect, the process includes a preselection to recover DNA including signal or secretion sequences. In this manner it is possible to select from the genomic DNA population by hybridization as hereinabove described only DNA which includes a signal or secretion sequence. The following paragraphs describe the protocol for this embodiment of the invention, the nature and function of secretion signal sequences in general and a specific exemplary application of such sequences to an assay or selection process. [0107]
  • A particularly preferred embodiment of this aspect further comprises, after (a) but before (b) above, the steps of: [0108]
  • (a i). contacting the single-stranded DNA population of (a) with a ligand-bound oligonucleotide probe that is complementary to a secretion signal sequence unique to a given class of proteins under conditions permissive of hybridization to form a double-stranded complex; [0109]
  • (a ii). contacting the double-stranded complex of (a i) with a solid phase specific binding partner for said ligand so as to produce a solid phase complex; [0110]
  • (a iii) separating the solid phase complex from the single-stranded DNA population of (a); [0111]
  • (a iv) releasing the members of the genomic population which had bound to said solid phase bound probe; and [0112]
  • (a v) separating the solid phase bound probe from the members of the genomic population which had bound thereto. [0113]
  • The DNA which has been selected and isolated to include a signal sequence is then subjected to the selection procedure hereinabove described to select and isolate therefrom DNA which binds to one or more probe DNA sequences derived from DNA encoding an enzyme(s) having the specified enzyme activity. [0114]
  • This procedure is described and exemplified in U.S. Ser. No. 08/692,002, filed Aug. 2, 1996. [0115]
  • In-vivo biopanning may be performed utilizing a FACS-based machine. Complex gene libraries are constructed with vectors which contain elements which stabilize transcribed RNA. For example, the inclusion of sequences which result in secondary structures such as hairpins which are designed to flank the transcribed regions of the RNA would serve to enhance their stability, thus increasing their half life within the cell. The probe molecules used in the biopanning process consist of oligonucleotides labeled with reporter molecules that only fluoresce upon binding of the probe to a target molecule (e.g. molecular beacons—see ref.). These probes are introduced into the recombinant cells from the library using one of several transformation methods. The probe molecules bind to the transcribed target mRNA resulting in DNA/RNA heteroduplex molecules. Binding of the probe to a target will yield a fluorescent signal which is detected and sorted by the FACS machine during the screening process. [0116]
  • Further, it is possible to combine all the above embodiments such that a normalization step is performed prior to generation of the expression library, the expression library is then generated, the expression library so generated is then biopanned, and the biopanned expression library is then screened using a high throughput cell sorting and screening instrument. Thus there are a variety of options: i.e. (i) one can just generate the library and then screen it; (ii) normalize the target DNA, generate the expression library and screen it; (iii) normalize, generate the library, biopan and screen; or (iv) generate, biopan and screen the library. [0117]
  • The library may, for example, be screened for a specified enzyme activity. For example, the enzyme activity screened for may be one or more of the six IUB classes; oxidoreductases, transferases, hydrolases, lyases, isomerases and ligases. The recombinant enzymes which are determined to be positive for one or more of the IUB classes may then be rescreened for a more specific enzyme activity. [0118]
  • Alternatively, the library may be screened for a more specialized enzyme activity. For example, instead of generically screening for hydrolase activity, the library may be screened for a more specialized activity, i.e. the type of bond on which the hydrolase acts. Thus, for example, the library may be screened to ascertain those hydrolases which act on one or more specified chemical functionalities, such as: (a) amide (peptide bonds), i.e. proteases; (b) ester bonds, i.e. esterases and lipases; (c) acetals, i.e., glycosidases etc. [0119]
  • The clones which are identified as having the specified enzyme activity may then be sequenced to identify the DNA sequence encoding an enzyme having the specified activity. Thus, in accordance with the present invention it is possible to isolate and identify: (i) DNA encoding an enzyme having a specified enzyme activity, (ii) enzymes having such activity (including the amino acid sequence thereof) and (iii) produce recombinant enzymes having such activity. [0120]
  • The present invention may be employed for example, to identify new enzymes having, for example, the following activities which may be employed for the following uses: [0121]
  • Lipase/Esterase [0122]
  • Enantioselective hydrolysis of esters (lipids)/thioesters [0123]
  • Resolution of racemic mixtures [0124]
  • Synthesis of optically active acids or alcohols from meso-diesters [0125]
  • Selective syntheses [0126]
  • Regiospecific hydrolysis of carbohydrate esters [0127]
  • Selective hydrolysis of cyclic secondary alcohols [0128]
  • Synthesis of optically active esters, lactones, acids, alcohols [0129]
  • Transesterification of activated/nonactivated esters [0130]
  • Interesterification [0131]
  • Optically active lactones from hydroxyesters [0132]
  • Regio- and enantioselective ring opening of anhydrides [0133]
  • Detergents [0134]
  • Fat/Oil conversion [0135]
  • Cheese ripening [0136]
  • Protease [0137]
  • Ester/amide synthesis [0138]
  • Peptide synthesis [0139]
  • Resolution of racemic mixtures of amino acid esters [0140]
  • Synthesis of non-natural amino acids [0141]
  • Detergents/protein hydrolysis [0142]
  • Glycosidase/Glycosyl transferase [0143]
  • Sugar/polymer synthesis [0144]
  • Cleavage of glycosidic linkages to form mono, di- and oligosaccharides [0145]
  • Synthesis of complex oligosaccharides [0146]
  • Glycoside synthesis using UDP-galactosyl transferase [0147]
  • Transglycosylation of disaccharides, glycosyl fluorides, aryl galactosides [0148]
  • Glycosyl transfer in oligosaccharide synthesis [0149]
  • Diastereoselective cleavage of (-glucosylsulfoxides [0150]
  • Asymmetric glycosylations [0151]
  • Food processing [0152]
  • Paper processing [0153]
  • Phosphatase/Kinase [0154]
  • Synthesis/hydrolysis of phosphate esters [0155]
  • Regio-, enantioselective phosphorylation [0156]
  • Introduction of phosphate esters [0157]
  • Synthesize phospholipid precursors [0158]
  • Controlled polynucleotide synthesis [0159]
  • Activate biological molecule [0160]
  • Selective phosphate bond formation without protecting groups [0161]
  • Mono/Dioxygenase [0162]
  • Direct oxyfunctionalization of unactivated organic substrates [0163]
  • Hydroxylation of alkane, aromatics, steroids [0164]
  • Epoxidation of alkenes [0165]
  • Enantioselective sulphoxidation [0166]
  • Regio- and stereoselective Bayer-Villiger oxidations [0167]
  • Haloperoxidase [0168]
  • Oxidative addition of halide ion to nucleophilic sites [0169]
  • Addition of hypohalous acids to olefinic bonds [0170]
  • Ring cleavage of cyclopropanes [0171]
  • Activated aromatic substrates converted to ortho and para derivatives [0172]
  • 1.3 diketones converted to 2-halo-derivatives [0173]
  • Heteroatom oxidation of sulfur and nitrogen containing substrates [0174]
  • Oxidation of enol acetates, alkynes and activated aromatic rings [0175]
  • Lignin peroxidase/Diarylpropane peroxidase [0176]
  • Oxidative cleavage of C—C bonds [0177]
  • Oxidation of benzylic alcohols to aldehydes [0178]
  • Hydroxylation of benzylic carbons [0179]
  • Phenol dimerization [0180]
  • Hydroxylation of double bonds to form diols [0181]
  • Cleavage of lignin aldehydes [0182]
  • Epoxide hydrolase [0183]
  • Synthesis of enantiomerically pure bioactive compounds [0184]
  • Regio- and enantioselective hydrolysis of epoxide [0185]
  • Aromatic and olefinic epoxidation by monooxygenases to form epoxides [0186]
  • Resolution of racemic epoxides [0187]
  • Hydrolysis of steroid epoxides [0188]
  • Nitrile hydratase/nitrilase [0189]
  • Hydrolysis of aliphatic nitrites to carboxamides [0190]
  • Hydrolysis of aromatic, heterocyclic, unsaturated aliphatic nitrites to corresponding acids [0191]
  • Hydrolysis of acrylonitrile [0192]
  • Production of aromatic and carboxamides, carboxylic acids (nicotinamide, picolinamide, isonicotinamide) [0193]
  • Regioselective hydrolysis of acrylic dinitrile (-amino acids from (-hydroxynitriles [0194]
  • Transaminase [0195]
  • Transfer of amino groups into oxo-acids [0196]
  • Amidase/Acylase [0197]
  • Hydrolysis of amides, amidines, and other C—N bonds [0198]
  • Non-natural amino acid resolution and synthesis [0199]
  • As indicated, the present invention also offers the ability to screen for other types of bioactivities. For instance, the ability to select and combine desired components from a library of polyketides and postpolyketide biosynthesis genes for generation of novel polyketides for study is appealing. The method(s) of the present invention make it possible to and facilitate the cloning of novel polyketide synthases, since one can generate gene banks with clones containing large inserts (especially when using vectors which can accept large inserts, such as the f-factor based vectors), which facilitates cloning of gene clusters. [0200]
  • Preferably, the gene cluster or pathway DNA is ligated into a vector, particularly wherein a vector further comprises expression regulatory sequences which can control and regulate the production of a detectable protein or protein-related array activity from the ligated gene clusters. Use of vectors which have an exceptionally large capacity for exogenous DNA introduction are particularly appropriate for use with such gene clusters and are described by way of example herein to include the f-factor (or fertility factor) of [0201] E. coli. As previously indicated, this f-factor of E. coli is a plasmid which affect high-frequency transfer of itself during conjugation and is ideal to achieve and stably propagate large DNA fragments, such as gene clusters from mixed microbial samples. Other examples of vectors include cosmids, bacterial artificial chromosome vectors, and P1 vectors.
  • Lambda vectors can also accommodate relatively large DNA molecules, have high cloning and packaging efficiencies and are easy to handle and store compared to plasmid vectors. (-ZAP vectors (Stratagene Cloning Systems, Inc.) have a convenient subcloning feature that allows clones in the vector to be excised with helper phage into the pBluescript phagemid, eliminating the time involved in subcloning. The cloning site in these vectors lies downstream of the lac promoter. This feature allows expression of genes whose endogenous promoter does not function in [0202] E. coli.
  • The following describes the total number of assays required to test an entire library: [0203]
  • The two main factors which govern the total number of clones that can be pooled and simultaneously screened are (i) the level of gene expression and (ii) enzyme assay sensitivity. As estimate of the level of gene expression is that each [0204] E. coli cell infected with lambda will produce 103 copies of the gene product from the insert. FACS instruments are sufficiently sensitive to detect about 500 to 1000 Fluorescein molecules.
  • In order to assess the total number of clones to be tested (e.g., the number of genome equivalents) a statistical analysis was performed. Assuming that mechanical shearing and gradient purification results in a normal distribution of DNA fragment sizes with a mean of 4.5 kbp and variance of 1 kbp, the fraction represented of all possible 1 kbp sequences in a 1.8 Mbp genome is plotted in FIG. 3 as a function of increasing genome equivalents. [0205]
  • Based on these results, approximately 2,000 clones (5 genome equivalents) must be screened to achieve a ˜90% probability of obtaining a particular gene. This represents the point of maximal efficiency for library throughput. Assuming that a complex environmental library contains about 1000 different organisms, at least 2,000,000 clones have to be screened to achieve a >90% probability of obtaining a particular gene. This number rises dramatically assuming that the organisms differ vastly in abundance in natural populations. [0206]
  • Substrate can be administered to the cells before or during the process of the cell sorting analysis. In either case a solution of the substrate is made up and the cells are contacted therewith. When done prior to the cell sorting analysis this can be by making a solution which can be administered to the cells while in culture plates or other containers. The concentration ranges for substrate solutions will vary according to the substrate utilized. Commercially available substrates will generally contain instructions on concentration ranges to be utilized for, for instance, cell staining purposes. These ranges may be employed in the determination of an optimal concentration or concentration range to be utilized in the present invention. The substrate solution is maintained in contact with the cells for a period of time and at an appropriate temperature necessary for the substrate to permeablize the cell membrane. Again, this will vary with substrate. Instruments which deliver reagents in stream such as by poppet valves which seal openings in the flow path until activated to permit introduction of reagents (e.g. substrate) into the flow path in which the cells are moving through the analyzer can be employed for substrate delivery. [0207]
  • The substrate is one which is able to enter the cell and maintain its presence within the cell for a period sufficient for analysis to occur. It has generally been observed that introduction of the substrate into the cell across the cell membrane occurs without difficulty. It is also preferable that once the substrate is in the cell it not “leak” back out before reacting with the biomolecule being sought to an extent sufficient to product a detectable response. Retention of the substrate in the cell can be enhanced by a variety of techniques. In one, the substrate compound is structurally modified by addition of a hydrophobic tail. In another certain preferred solvents, such as DMSO or glycerol, can be administered to coat the exterior of the cell. Also the substrate can be administered to the cells at reduced temperature which has been observed to retard leakage of the substrate from the cell's interior. [0208]
  • A broad spectrum of substrates can be used which are chosen based on the type of bioactivity sought. In addition where the bioactivity being sought is in the same class as that of other biomolecules for which a number have known substrates, the bioactivity can be examined using a cocktail of the known substrates for the related biomolecules which are already known. For example, substrates are known for approximately 20 commercially available esterases and the combination of these known substrates can provide detectable, if not optimal, signal production. Substrates are also known and available for glycosidases, proteases, phosphatases, and monoxygenases. [0209]
  • The substrate interacts with the target biomolecule so as to produce a detectable response. Such responses can include chromogenic or fluorogenic responses and the like. The detectable species can be one which results from cleavage of the substrate or a secondary molecule which is so affected by the cleavage or other substrate/biomolecule interaction to undergo a detectable change. Innumerable examples of detectable assay formats are known from the diagnostic arts which use immunoassay, chromogenic assay, and labeled probe methodologies. [0210]
  • Several enzyme assays described in the literature are built around the change in fluorescence which results when the phenolic hydroxyl (or anilino amine) becomes deacylated (or dealkylated) by the action of the enzyme. FIG. 7 shows the basic principle for this type of enzyme assay for deacylation. Any emission or activation of fluorescent wavelengths as a result of any biological process are defined herein as bioactive fluoresence. [0211]
  • In comparison to calorimetric assays, fluorescent based assays are very sensitive, which is a major criteria for single cell assays. There are two main factors which govern the screening of a recombinant enzyme in a single cell: i) the level of gene expression, and ii) enzyme assay sensitivity. To estimate the level of gene expression one can determine how many copies of the gene product will be produced by the host cell given the vector. For instance, one can assume that each [0212] E. coli cell infected with pBluescript phagemid (Stratagene Cloning Systems, Inc.) will produce ˜103 copies of the gene product from the insert. The FACS instruments are capable of detecting about 500 to 1,000 fluorescein molecules per cell. Assuming that one enzyme turns over at least one fluorescein based substrate molecule, one cell will display enough fluorescence to be detected by the optics of a fluorescence-activated cell sorter (FACS).
  • Several methods have been described for using reporter genes to measure gene expression. These reporter genes encode enzymes not ordinarily found in the type of cell being studied, and their unique activity is monitored to determine the degree of transcription. Nolan et al., developed a technique to analyze (-galactosidase expression in mammalian cells employing fluorescein-di-(-D-galactopyranoside (FDG) as a substrate for (-galactosidase, which releases fluorescein, a product that can be detected by a fluorescence-activated cell sorter (FACS) upon hydrolysis (Nolan et al., 1991). A problem with the use of FDG is that if the assay is performed at room temperature, the fluorescence leaks out of the positively stained cells. A similar problem was encountered in other studies of (-galactosidase measurements in mammalian cells and yeast with FDG as well as other substrates (Nolan et al, 1988; Wittrup et al., 1988). Performing the reaction at 0° C. appreciably decreased the extent of this leakage of fluorescence (Nolan et al., 1988). However this low temperature is not adaptable for screening for, for instance, high temperature (-galactosidases. Other fluorogenic substrates have been developed, such as 5-dodecanoylamino fluorescein di-(-D-galactopyranoside (C[0213] 12-FDG) (Molecular Probes) which differs from FDG in that it is a lipophilic fluorescein derivative that can easily cross most cell membranes under physiological culture conditions. The green fluorescent enzymatic hydrolysis product is retained for hours to days in the membrane of those cells that actively express the lacZ reporter gene. In animal cells C12-FDG was a much better substrate, giving a signal which was 100 times higher than the one obtained with FDG (Plovins et al., 1994). However in Gram negative bacteria like E. coli, the outer membrane functions as a barrier for the lipophilic molecule C12-FDG and it only passes through this barrier if the cells are dead or damaged (Plovins et al). The fact that C12 retains FDG substrate inside the cells indicates that the addition of unpolarized tails may be used for retaining substrate inside the cells with respect to other enzyme substrates.
  • The abovementioned (-galactosidase assays may be employed to screen single [0214] E. coli cells, expressing recombinant (-D-galactosidase isolated from a hyperthermophilic archaeon such as Sulfolobus solfataricus, on a fluorescent microscope. Cells are cultivated overnight, centrifuged and washed in deionized water and stained with FDG. To increase enzyme activity, cells are heated to 70° C. for 30 minutes and examined with a fluorescence phase contrast microscope. E. coli cell suspensions of the (-galactosidase expressing clone stained with C12-FDG show a very bright fluorescence inside single cells (FIG. 8).
  • The heat treatment of [0215] E. coli permeabilizes the cells to allow the substrate to pass through the membrane. Control strains containing plasmid DNA without insert and stained with the same procedure show no fluorescence. Phase contrast microscopy of heated cells reveals that cells maintain their structural integrity up to 2 hours if heated up to 70° C. The lipophilic tail of the modified fluorescein-di-(-D-galactopyranoside prevents leakage of the molecule, even at elevated temperatures. The attachment of a lipophilic carbon chain changes the solubility of substrates tremendously. Thus, substrates containing lipophilic carbon chains can be generated and utilized as screening substrates in the present invention. For instance, the following activities may be detected utilized the indicated substrates. Different methods can be employed for loading substrate inside the cells. Additionally, DMSO can be used as solvent up to a concentration of 50% in water to dissolve and load substrates without significantly dropping the viability of E. coli. Enzyme activity and leakage can be monitored with fluorescence microscopy.
  • Lipases/Esterases [0216]
  • An acylated derivative of fluorescein can be used to detect esterases such as lipases. The fluorophore is hydrolyzed from the derivative to generate a signal. Acylated derivatives of fluorescein can be synthesized according to FIG. 9. Nine molar equivalents of lauric anhydride triethylamine and N,N-diisopropylethylamine are added to a solution of fluoresceinamine in chloroform. After the reaction is complete, the product 5-dodecanoyl-aminofluorescein-di-dodecanoic acid (C[0217] 12-FDC12) is recrystallized.
  • Proteases [0218]
  • Proteases can be assayed in the same way as the esterases, with an amide being cleaved instead of an ester. There are now well over 100 different protease substrates available with an acylated fluorophore at the scissile bond. Rhodamine derivatives (FIG. 10), have more lipophilic characteristics compared to fluorescein protrease substrates, therefore they make good substrates for more general assays. [0219]
  • Monooxygenases (Dealkylases) [0220]
  • Compounds such as that depicted in FIG. 11 can be used to detected monooxygenases. Hydroxylation of the ethyl group in the compound results in the release of the resorufin fluorophore. Several unmodified coumarin derivatives are also commercially available. [0221]
  • A variety of types of high throughput cell sorting instruments can be used with the present invention. First there is the FACS cell sorting instrument which has the advantage of a very high throughput and individual cell analysis. Other types of instruments which can be used are robotics instruments and time-resolved fluorescence instruments, which can actually measure the fluorescence from a single molecule over an elapsed period of time. Since they are measuring a single molecule, they can simultaneously determine its molecular weight, however their throughput is not as high as the FACS cell sorting instruments. [0222]
  • When screening with the FACS instrument, the trigger parameter is set with logarithmic forward side scatter. The fluorescent signals of positive clones emitted by fluorescein or other fluorescent substrates is distinguished by means of a dichroic mirror and acquired in log mode. For example, “active” clones can be sorted and deposited into microtiter plates. When sorting clones from libraries constructed from single organisms or from small microbial consortia, approximately 50 clones can be sorted into individual microtiter plate wells. When complex environmental mega-libaries (i.e. libraries containing ˜10[0223] 8 clones which represent >100 organisms) about 500 expressing clones should be collected.
  • Plasmid DNA can then be isolated from the sorted clones using any commercially available automated miniprep machine, such as that from Autogen. The plasmids are then retransformed into suitable expression hosts and assayed for activity utilizing chromogenic agar plate based or automated liquid format assays. Confirmed expression clones can then undergo RFLP analysis to determine unique clones prior to sequencing. The inserts which contain the unique esterase clones can be sequenced, open reading frames (ORF's) identified and the genes PCR subcloned for overexpression. Alternatively, expressing clones can be “bulk sorted” into single tubes and the plasmid inserts recovered as amplified products, which are then subcloned and transformed into suitable vector-hosts systems for rescreening. [0224]
  • Encapsulation techniques may be employed to localize signal, even in cases where cells are no longer viable. Gel microdrops (GMDs) are small (25 to Sum in diameter) particles made with a biocompatible matrix. In cases of viable cells, these microdrops serve as miniaturized petri dishes because cell progeny are retained next to each other, allowing isolation of cells based on clonal growth. The basic method has a significant degree of automation and high throughput; after the colony size signal boundaries are established, about 10[0225] 6 GMDs per hour can be automatically processed. Cells are encapsulated together with substrates and particles containing a positive clones are sorted. Fluorescent substrate labeled glass beads can also be loaded inside the GMDs. In cases of non-viable cells, GMDs can be employed to ensure localization of signal.
  • After viable or non-viable cells, each containing a different expression clone from the gene library are screened on a FACS machine, and positive clones are recovered, DNA is isolated from positive clones. The DNA can then be amplified either in vivo or in vitro by utilizing any of the various amplification techniques known in the art. In vivo amplification would include transformation of the clone(s) or subclone(s) of the clones into a viable host, followed by growth of the host. In vitro amplification can be performed using techniques such as the polymerase chain reaction. [0226]
  • Clones found to have the bioactivity for which the screen was performed can also be subjected to directed mutagenesis to develop new bioactivities with desired properties or to develop modified bioactivities with particularly desired properties that are absent or less pronounced in the wild-type enzyme, such as stability to heat or organic solvents. Any of the known techniques for directed mutagenesis are applicable to the invention. For example, particularly preferred mutagenesis techniques for use in accordance with the invention include those described below. [0227]
  • The term “error-prone PCR” refers to a process for performing PCR under conditions where the copying fidelity of the DNA polymerase is low, such that a high rate of point mutations is obtained along the entire length of the PCR product. Leung, D. W., et al., Technique, 1:11-15 (1989) and Caldwell, R. C. & Joyce G. F., PCR Methods Applic., 2:28-33 (1992). [0228]
  • The term “oligonucleotide directed mutagenesis” refers to a process which allows for the generation of site-specific mutations in any cloned DNA segment of interest. Reidhaar-Olson, J. F. & Sauer, R. T., et al., Science, 241:53-57 (1988). [0229]
  • The term “assembly PCR” refers to a process which involves the assembly of a PCR product from a mixture of small DNA fragments. A large number of different PCR reactions occur in parallel in the same vial, with the products of one reaction priming the products of another reaction. [0230]
  • The term “sexual PCR mutagenesis” (also known as “DNA shuffling”) refers to forced homologous recombination between DNA molecules of different but highly related DNA sequence in vitro, caused by random fragmentation of the DNA molecule based on sequence homology, followed by fixation of the crossover by primer extension in a PCR reaction. Stemmer, W. P., PNAS, USA, 91:10747-10751 (1994). [0231]
  • The term “in vivo mutagenesis” refers to a process of generating random mutations in any cloned DNA of interest which involves the propagation of the DNA in a strain of [0232] E. coli that carries mutations in one or more of the DNA repair pathways. These “mutator” strains have a higher random mutation rate than that of a wild-type parent. Propogating the DNA in one of these strains will eventually generate random mutations within the DNA.
  • The term “cassette mutagenesis” refers to any process for replacing a small region of a double stranded DNA molecule with a synthetic oligonucleotide “cassette” that differs from the native sequence. The oligonucleotide often contains completely and/or partially randomized native sequence. [0233]
  • The term “recursive ensemble mutagenesis” refers to an algorithm for protein engineering (protein mutagenesis) developed to produce diverse populations of phenotypically related mutants whose members differ in amino acid sequence. This method uses a feedback mechanism to control successive rounds of combinatorial cassette mutagenesis. Arkin, A. P. and Youvan, D. C., PNAS, USA, 89:7811-7815 (1992). [0234]
  • The term “exponential ensemble mutagenesis” refers to a process for generating combinatorial libraries with a high percentage of unique and functional mutants, wherein small groups of residues are randomized in parallel to identify, at each altered position, amino acids which lead to functional proteins, Delegrave, S. and Youvan, D. C., Biotechnology Research, 11:1548-1552 (1993); and random and site-directed mutagenesis, Arnold, F. H., Current Opinion in Biotechnology, 4:450-455 (1993). [0235]
  • All of the references mentioned above are hereby incorporated by reference in their entirety. Each of these techniques is described in detail in the references mentioned. [0236]
  • DNA can be mutagenized, or “evolved”, utilizing any one or more of these techniques, and rescreened on the FACS machine to identify more desirable clones. Internal control reference genes which either express fluorescing molecules, such as those encoding green fluorescent protein, or encode proteins that can turnover fluorescing molecules, such as beta-galactosidase, can be utilized. These internal controls should optimally fluoresce at a wavelength which is different from the wavelength at which the molecule used to detect the evolved molecule(s) emits. DNA is evolved, recloned in a vector which co-expresses these proteins or molecules, transformed into an appropriate host organism, and rescreened utilizing the FACS machine to identify more desirable clones. [0237]
  • An important aspect of the invention is that cells are being analyzed individually. However other embodiments are contemplated which involve pooling of cells and multiple passage screen. This provides for a tiered analysis of biological activity from more general categories of activity, i.e. categories of enzymes, to specific activities of principle interest such as enzymes of that category which are specific to particular substrate molecules. [0238]
  • Members of these libraries can be encapsulated in gel microdroplets, exposed to substrates of interest, such as transition state analogs, and screened based on binding via FACS sorting for activities of interest. [0239]
  • It is anticipated with the present invention that one could employ mixtures of substrates to simultaneously detect multiple activities of interest simultaneously or sequentially. FACS instruments can detect molecules that fluoresce at different wavelengths, hence substrates which fluoresce at different wavelengths and indicate different activities can be employed. [0240]
  • The fluorescence activated cell sorting screening method of the present invention allows one to assay several million clones per hour for a desired bioactivity. This technique provides an extremely high throughput screening process necessary for the screening of extreme biodiverse environmental libraries. [0241]
  • The invention will now be illustrated by the following working examples, which are in no way a limitation thereof. [0242]
  • EXAMPLE 1 DNA Isolation and Library Construction
  • The following outlines the procedures used to generate a gene library from an environmental sample. [0243]
  • Isolate DNA. [0244]
  • IsoQuick Procedure as per manufacturer's instructions (Orca, Research Inc., Bothell, Wash.). [0245]
  • Normalization. [0246]
  • DNA can be normalized according to Example 2. [0247]
  • Shear DNA [0248]
  • Vigorously push and pull DNA through a 25G double-hub needle and 1-cc syringes about 500 times. [0249]
  • Check a small amount (0.5 (g) on a 0.8% agarose gel to make sure the majority of the DNA is in the desired size range (about 3-6 kb). [0250]
  • Blunt DNA [0251]
  • Add: [0252]
    H2O to a final volume of 405 (l
    45 (l 10X Mung Bean Buffer
    2.0 (l Mung Bean Nuclease (150 u/(l)
  • Incubate 37(C, 15 minutes. [0253]
  • Phenol/chloroform extract once. [0254]
  • Chloroform extract once. [0255]
  • Add 1 ml ice cold ethanol to precipitate. [0256]
  • Place on ice for 10 minutes. [0257]
  • Spin in microfuge, high speed, 30 minutes. [0258]
  • Wash with 1 ml 70% ethanol. [0259]
  • Spin in microfuge, high speed, 10 minutes and dry. [0260]
  • Methylate DNA [0261]
  • Gently resuspend DNA in 26 (l TE. [0262]
  • Add: [0263]
    4.0 (l 10X EcoR I Methylase Buffer
    0.5 (l SAM (32 mM)
    5.0 (l EcoR I Methylase (40 u/(l)
  • Incubate 37(, 1 hour. [0264]
  • Insure Blunt Ends [0265]
  • Add to the methylation reaction: [0266]
    5.0 (l 100 mM MgCl2
    8.0 (l dNTP mix (2.5 mM of each dGTP, dATP, dTTP, dCTP)
    4.0 (l Klenow (5 u/(l)
  • Incubate 12(C, 30 minutes. [0267]
  • Add 450 (l 1× STE. [0268]
  • Phenol/chloroform extract once. [0269]
  • Chloroform extract once. [0270]
  • Add 1 ml ice cold ethanol to precipitate and place on ice for 10 minutes. [0271]
  • Spin in microfuge, high speed, 30 minutes. [0272]
  • Wash with 1 ml 70% ethanol. [0273]
  • Spin in microfuge, high speed, 10 minutes and dry. [0274]
  • Adaptor Ligation [0275]
  • Gently resuspend DNA in 8 (l EcoRI adaptors (from Stratagene's cDNA Synthesis Kit). [0276]
  • Add: [0277]
    1.0 (l 10X Ligation Buffer
    1.0 (l 10 mM rATP
    1.0 (l T4 DNA Ligase (4Wu/ (l)
  • Incubate 4(C, 2 days. [0278]
  • Phosphorylate Adaptors [0279]
  • Heat kill ligation reaction 70(C, 30 minutes. [0280]
  • Add: [0281]
    1.0 (l 10X Ligation Buffer
    2.0 (l 10 mM rATP
    6.0 (l H2O
    1.0 (l Polynucleotide kinase (PNK)
  • Incubate 37(C, 30 minutes. [0282]
  • Add 31 (l H[0283] 2O and 5 (l 10× STE.
  • Size fractionate on a Sephacryl S-500 spin column (pool fractions 1-3). [0284]
  • Phenol/chloroform extract once. [0285]
  • Chloroform extract once. [0286]
  • Add ice cold ethanol to precipitate. [0287]
  • Place on ice, 10 minutes. [0288]
  • Spin in microfuge, high speed, 30 minutes. [0289]
  • Wash with 1 ml 70% ethanol. [0290]
  • Spin in microfuge, high speed, 10 minutes and dry. [0291]
  • Resuspend in 10.5 (l TE buffer. [0292]
  • Do not plate assay. Instead, ligate directly to arms as above except use 2.5 (l of DNA and no water. [0293]
  • Sucrose Gradient (2.2 ml) Size Fractionation [0294]
  • Heat sample to 65(C, 10 minutes. [0295]
  • Gently load on 2.2 ml sucrose gradient. [0296]
  • Spin in mini-ultracentrifuge, 45K, 20(C, 4 hours (no brake). [0297]
  • Collect fractions by puncturing the bottom of the gradient tube with a 20G needle and allowing the sucrose to flow through the needle. Collect the first 20 drops in a Falcon 2059 tube then collect 10 l-drop fractions (labelled 1-10). Each drop is about 60 (l in volume. [0298]
  • Run 5 (l of each fraction on a 0.8% agarose gel to check the size. [0299]
  • Pool fractions 1-4 (about 10-1.5 kb) and, in a separate tube, pool fractions 5-7 (about 5-0.5 kb). [0300]
  • Add 1 ml ice cold ethanol to precipitate and place on ice for 10 minutes. [0301]
  • Spin in microfuge, high speed, 30 minutes. [0302]
  • Wash with 1 ml 70% ethanol. [0303]
  • Spin in microfuge, high speed, 10 minutes and dry. [0304]
  • Resuspend each in 10 (l TE buffer. [0305]
  • Test Ligation to Lambda Arms [0306]
  • Plate assay to get an approximate concentration. Spot 0.5 (l of the sample on agarose containing ethidium bromide along with standards (DNA samples of known concentration). View in UV light and estimate concentration compared to the standards. Fraction 1-4=>1.0 (g/(l. Fraction 5-7=500 ng/(l. [0307]
  • Prepare the following ligation reactions (5 (l reactions) and incubate 4(C, overnight: [0308]
    T4 DNA
    10× Lambda Ligase
    Ligase 10 mM arms Insert (4
    Sample H2O Buffer rATP (ZAP) DNA Wu/(1)
    Fraction 1-4 0.5 0.5 0.5 1.0 2.0 0.5
    (1 (1 (1 (1 (1 (1
    Fraction 5-7 0.5 0.5 0.5 1.0 2.0 0.5
    (1 (1 (1 (1 (1 (1
  • Test Package and Plate [0309]
  • Package the ligation reactions following manufacturer's protocol. Stop packaging reactions with 500 (l SM buffer and pool packaging that came from the same ligation. [0310]
  • Titer 1.0 (l of each on appropriate host (OD[0311] 600=1.0) [XLI-Blue MRF]
  • Add 200 (l host (in mM MgSO[0312] 4) to Falcon 2059 tubes
  • Inoculate with 1 (l packaged phage [0313]
  • Incubate 37(C, 15 minutes [0314]
  • Add about 3 ml 48(C top agar [0315]
  • [50ml stock containing 150 (l IPTG (0.5M) and 300 (l X-GAL (350 mg/ml)][0316]
  • Plate on 100mm plates and incubate 37(C, overnight. [0317]
  • Amplification of Libraries (5.0×10[0318] 5 recombinants from each library)
  • Add 3.0 ml host cells (OD[0319] 600=1.0) to two 50 ml conical tube.
  • Inoculate with 2.5×10[0320] 5 pfu per conical tube.
  • Incubate 37(C, 20 minutes. [0321]
  • Add top agar to each tube to a final volume of 45 ml. [0322]
  • Plate the tube across five 150 mm plates. [0323]
  • Incubate 37(C, 6-8 hours or until plaques are about pin-head in size. [0324]
  • Overlay with 8-10 ml SM Buffer and place at 4(C overnight (with gentle rocking if possible). [0325]
  • Harvest Phage [0326]
  • Recover phage suspension by pouring the SM buffer off each plate into a 50-ml conical tube. [0327]
  • Add 3 ml chloroform, shake vigorously and incubate at room temperature, 15 minutes. [0328]
  • Centrifuge at 2K rpm, 10 minutes to remove cell debris. [0329]
  • Pour supernatant into a sterile flask, add 500 (l chloroform. [0330]
  • Store at 4(C. [0331]
  • Titer Amplified Library [0332]
  • Make serial dilutions: [0333]
  • 10[0334] −5=1 (l amplified phage in 1 ml SM Buffer
  • 10[0335] −6=1 (l of the 10−3 dilution in 1 ml SM Buffer
  • Add 200 (l host (in 10 mM MgSO[0336] 4) to two tubes.
  • Inoculate one with 10 (l 10[0337] −6 dilution (10−6).
  • Inoculate the other with 1 (l 10[0338] −6 dilution (10−6)
  • Incubate 37(C, 15 minutes. [0339]
  • Add about 3 ml 48(C top agar. [0340]
  • [50 ml stock containing 150 (l IPTG (0.5M) and 375 (l X-GAL (350 mg/ml)][0341]
  • Plate on 100 mm plates and incubate 37(C, overnight. [0342]
  • Excise the ZAP II library to create the pBluescript library according to manufacturers protocols (Stratagene). [0343]
  • EXAMPLE 2 Normalization
  • Prior to library generation, purified DNA can be normalized. DNA is first fractionated according to the following protocol: [0344]
  • Sample composed of genomic DNA is purified on a cesium-chloride gradient. The cesium chloride (Rf=1.3980) solution is filtered through a 0.2 (m filter and 15 ml is loaded into a 35 ml OptiSeal tube (Beckman). The DNA is added and thoroughly mixed. Ten micrograms of bis-benzimide (Sigma; Hoechst 33258) is added and mixed thoroughly. The tube is then filled with the filtered cesium chloride solution and spun in a VTi50 rotor in a Beckman L8-70 Ultracentrifuge at 33,000 rpm for 72 hours. [0345]
  • Following centrifugation, a syringe pump and fractionator (Brandel Model 186) are used to drive the gradient through an ISCO UA-5 UV absorbance detector set to 280 nm. Peaks representing the DNA from the organisms present in an environmental sample are obtained. Eubacterial sequences can be detected by PCR amplification of DNA encoding rRNA from a 10-fold dilution of the [0346] E. coli peak using the following primers to amplify:
  • Forward primer: [0347]
    Forward primer:
    5′-AGAGTTTGATCCTGGCTCAG-3′
    Reverse primer:
    5′-GGTTACCTTGTTACGACTT-3′
  • Recovered DNA is sheared or enzymatically digested to 3-6 kb fragments. Lone-linker primers are ligated and the DNA is sized selected. Size-selected DNA is amplified by PCR, if necessary. [0348]
  • Normalization is then accomplished as follows: [0349]
  • Double-stranded DNA sample is resuspended in hybridization buffer (0.12 M NaH[0350] 2PO4, pH 6.8/0.82 M NaCl/1 mM EDTA/0.1% SDS).
  • Sample is overlaid with mineral oil and denatured by boiling for 10 minutes. [0351]
  • Sample is incubated at 68(C for 12-36 hours. [0352]
  • Double-stranded DNA is separated from single-stranded DNA according to standard protocols (Sambrook, 1989) on hydroxyapatite at 60(C. [0353]
  • The single-stranded DNA fraction is desalted and amplified by PCR. [0354]
  • The process is repeated for several more rounds (up to 5 or more). [0355]
  • EXAMPLE 3 Cell Staining Prior to FACS Screening
  • Gene libraries, including those generated as described in Example 1, can be screened for bioactivities of interest on a FACS machine as indicated herein. A screening process begins with staining of the cells with a desirable substrate according to the following example. [0356]
  • A gene library is made from the hyperthermophilic archaeon [0357] Sulfulobus solfataricus in the (-ZAPII vector according to the manufacturers instructions (Stratagene Cloning Systems, Inc., La Jolla, Calif.), and excised into the pBluescript plasmid according to the manufacturers instructions (Stratagene) . DNA was isolated using the IsoQuick DNA isolation kit according to the manufacturers instructions (Orca, Inc., Bothell, Wash.).
  • To screen for (-galactosidase activity, cells are stained as follows: [0358]
  • Cells are cultivated overnight at 37(C in an orbital shaker at 250rpm [0359]
  • Cells are centrifuged to collect about 2×10[0360] 7 cells (0.1 ml of the culture)
  • Cells are resuspended in 1 ml of deionized water, and stained with C[0361] 12-Fluoroscein-Di-(-D-galactopyranoside (FDG) as follows:
    0.5 ml Cells
    50 (l C12-FDG staining solution (1 mg C12-FDG in 1 ml
    of a mixture of 98% H2O, 1% DMSO, 1% EtOH)
    50 (l Propidium iodide (PI) staining solution
    (50 (g/ml of distilled water)
  • Sample is incubated in the dark at 37(C with shaking at 150 rpm for 30 minutes. [0362]
  • Cells are then heated to 70(C for 30 minutes (this step can be avoided if sample is not derived from a hyperthermophilic organism). [0363]
  • EXAMPLE 4 Screening of Expression Libraries by FACS and Recovery of Genetic Information of Sorted Organisms
  • The excised (-ZAP II library is incubated for 2 hours and induced with IPTG. Cells are centrifuged, washed and stained with the desired enzyme substrate, for example C[0364] 12-Fluoroscein-Di-(-D-galactopyranoside (FDG) as in Example 3. Clones are sorted on a commercially available FACS machine, and positives are collected. Cells are lysed according to standard techniques (Current Protocols in Molecular Biology, 1987) and plasmids are transformed into new host by electroporation using standard techniques. Transformed cells are plated for secondary screening. The procedure is illustrated in FIG. 5.
  • Sorted organisms can be grown and plated for secondary screening. [0365]
  • EXAMPLE 5 Sorting Directly on Microtiter Plates
  • Cells can be sorted in a FACS instrument directly on microtiter plates in accordance with the present invention. Sorting in this fashion facilitates downstream processing of positive clones. [0366]
  • [0367] E. coli cells containing (-galactosidase genes are exposed to a staining solution in accordance with Example 3. These cells are then left to sit on ice for three minutes. For the cell sorting procedure they are diluted 1:100 in deionized water or in Phospate Buffered Saline buffer solution according to the manufacturers protocols for cell sorting. The cells are then sorted by the FACS instrument into microtiter plates, one cell per well. The sorting criteria is fluorescein fluorescence indicating (-galactosidase activity or PI for indicating the staining of dead cells (unlike viable cells, dead cells have no membrane potential; hence PI remains in the cell with dead cells and is pumped out with live cells) . Results as observed on the microtiter plate are shown in FIG. 6.
  • Cited Literature
  • Alting-Mees, M. A., Short J. M., [0368] Nucl. Acids. Res. 1989, 17, 9494.
  • Hay, B. and Short, [0369] J. Strategies, 1992, 5, 16.
  • Enzyme Systems Products, Dublin Calif. 94568; Molecular Probes, Eugene, Oreg. 97402, Peninsula Laboratories, Belmont, Calif. 94002. [0370]
  • Adams, M. W. W., Kelly, R. M., [0371] Chemical and Engineering News, Dec. 18, 1995,
  • Amann, R., Ludwig, W., and Schleifer, K.-H. [0372] Microbiological Reviews, 1995, 59, 143.
  • Barnes, S. M., Fundyga, R. E., Jeffries, M. W. and Pace, N. R. [0373] Proc. Nat. Acad. Sci. USA , 1994, 91, 1609.
  • Bateson M. M., Wiegel, J., Ward, D. M., [0374] System. Appl. Microbiol. 1989, 12, 1-7
  • Betz, J. W., Aretz, W., Hartel, W., [0375] Cytometry, 1984, 5, 145-150
  • Davey, H. M., Kell, D. B., [0376] Microbiological Reviews, 1996, 60, 4, 641-696
  • Diaper, J. P., Edwards, C., [0377] J. Appl. Bacteriol., 1994, 77, 221-228
  • Enzyme Nomenclature , Academic Press: NY, 1992. [0378]
  • Faber, Biotransformation in organic chemistry 2nd edition, Springer Verlag, 1995. [0379]
  • Faber, U.S. Tonkovich and Gerber, Dept. of Energy Study, 1995. [0380]
  • Fiering, S. N., Roeder, M., Nolan, G. P., Micklem, D. R., Parcks, D. R., Herzenberg, L. A. [0381] Cytometry, 1991, 12, 291-301.
  • Giovannoni, S. J., Britschgi, T. B., Mover, C. L., Field, K. G., [0382] Nature, 1990 345, 60-63
  • Murray, M. G., and Thompson, W. F., [0383] Nucl. Acids Res., 1980, 8, 4321-4325
  • Nolan, G. P., Fiering, S., Nicolas, J., F., Herzenberg, L. A., [0384] Proc. Natl. Acad. Sci. USA, 1988, 85, 2603-2607.
  • Plovins A., Alvarez A. M., Ibanez M., Molina M., Nombela C., Appl. Environ. Microbiol., 1994, 60, 4638-4641. [0385]
  • Short, J. M., Fernandez, J. F. Sorge, J. A., and Huse, W. [0386] Nucleic Acids Res., 1988,16 , 7583-7600.
  • Short, J. M., and Sorge, J. A. [0387] Methods in Enzymology, 1992, 216, 495-508.
  • Tonkovich, A., L., Gerber, M. A., US Department of Energy, Office of Industrial Technology, Biological and Chemical Technologies Research Program under contract DE-AC06-76RLO 1830 [0388]
  • Torvsik, V. Goksoyr, J. Daae, F. L., [0389] Appl. and Environm. Microbiol. 1990, 56, 782-787
  • Wittrup, K. D., Bailey, J. E., Cytometry, 1988, 9, 394-404. [0390]
  • Wrotnowski, [0391] Genetic Engeneering News, Feb. 1, 1997.
    TABLE 1
    Habitat Cultured (%)
    Seawater 0.001-1.0
    Freshwater 0.25
    Mesotrophic lake 0.01-1.0
    Unpolluted esturine 0.1-3.0
    waters
    Activated sludge 1.0-15.0
    Sediments 0.25
    Soil 0.3

Claims (18)

What is claimed is:
1. A method for high throughput screening of prokaryotic genomic DNA samples to identify one or more enzymes encoded by the prokaryotic DNA of said sample, comprising the steps of :
a) generating a normalized, multispecific, prokaryotic expression library;
b) inserting bioactive substrates into samples of the library;
c) screening the samples with a fluorescent analyzer that detects bioactive fluorescence;
d) separating samples detected as positive for bioactive fluorescence; and
e) determining the DNA sequence of positive samples;
wherein the DNA sequence identifies and encodes an enzyme that catalyzes the bioactive substrate detected in step d).
2. The method of claim 1, wherein the enzyme is selected from the group consisting of lipases, esterases, proteases, glycosidases, glycosyl transferases, phosphatases, kinases, mono- and dioxygenases, haloperoxidases, lignin peroxidases, diarylpropane peroxidases, epozide hydrolases, nitrile hydratases, nitrilases, transaminases, amidases, and acylases.
3. The method of claim 1, wherein the prokaryotic expression library contains at least of about 2×106 clones.
4. The method of claim 1, wherein the sample is a prokaryotic cell.
5. The method of claim 4, wherein the prokaryotic cell is gram negative.
6. The method of claim 1, wherein the sample is encapsulated in a gel microdrop.
7. The method of claim 1, wherein the high-throughput screening step c) screens up to about 35 million samples per hour.
8. The method of claim 1, wherein the prokaryotic expression library contains extremophiles.
9. The method of claim 3, wherein the extremophiles are thermophiles.
10. The method of claim 3, wherein the extremeophiles are selected from the group consisting of hyperthermophiles, psychrophiles, halophiles, psychrotrophs, alkalophiles, and acidophiles.
11. The method of claim 1, wherein the bioactive substrate comprises C12FDG.
12. The method of claim 10, wherein the bioactive substrate further comprises a lipophilic tail.
13. The method of claim 1, wherein the the samples are heated before step b).
14. The method of claim 13, wherein the heating is in the range of about 70° C.
15. The method of claim 14, wherein the heating occurs in the range of about 30 minutes.
16. The method of claim 1, wherein the fluorescent analyzer comprises a FACS apparatus.
17. The method of claim 1, wherein the prokaryotic expression library is biopanned before step b).
18. The method of claim 1, including the additional steps of:
subjecting an enzyme encoded by the DNA identified in step d) to directed evolution comprising the steps of:
a) subjecting the enzyme to non-directed mutagenesis; and
b) screening mutant enzymes produced in step a) for a mutant enzyme that is stable at a temperature of at least in the range of about 60° C. and that has functioning enzymatic activity at a temperature at least 10° C. below its optimal temperature range and that catalyzes a greater amount of a catalytic substrate per a defined unit of time than the enzyme of step a).
US08/876,276 1997-06-16 1997-06-16 High throughput fluorescence-based screening for novel enzymes Abandoned US20030215798A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US08/876,276 US20030215798A1 (en) 1997-06-16 1997-06-16 High throughput fluorescence-based screening for novel enzymes

Applications Claiming Priority (37)

Application Number Priority Date Filing Date Title
US08/876,276 US20030215798A1 (en) 1997-06-16 1997-06-16 High throughput fluorescence-based screening for novel enzymes
PCT/US1998/012674 WO1998058085A1 (en) 1997-06-16 1998-06-16 High throughput screening for novel enzymes
US09/098,206 US6174673B1 (en) 1997-06-16 1998-06-16 High throughput screening for novel enzymes
JP50478299A JP2002505590A (en) 1997-06-16 1998-06-16 High-throughput screening of novel enzymes
AU81502/98A AU749587B2 (en) 1997-06-16 1998-06-16 High throughput screening for novel enzymes
CA 2294380 CA2294380A1 (en) 1997-06-16 1998-06-16 High throughput screening for novel enzymes
EP98931354A EP1009858A4 (en) 1997-06-16 1998-06-16 High throughput screening for novel enzymes
US09/444,112 US6972183B1 (en) 1997-06-16 1999-11-22 Capillary array-based enzyme screening
US09/687,219 US6794127B1 (en) 1997-06-16 2000-10-12 Capillary array-based sample screening
US09/738,871 US20010041333A1 (en) 1997-06-16 2000-12-15 High throughput screening for a bioactivity or biomolecule
US09/790,321 US20020048809A1 (en) 1997-06-16 2001-02-21 Capillary array-based sample screening
US09/848,651 US6806048B2 (en) 1997-06-16 2001-05-03 Method for high throughput screening of an environmental library
US09/848,083 US6602675B2 (en) 1997-06-16 2001-05-03 High throughput screening of mycelia for bioactivities or biomolecules
US09/848,095 US6872526B2 (en) 1997-06-16 2001-05-03 High throughput screening for novel Bioactivities
US09/848,185 US20020127560A1 (en) 1997-06-16 2001-05-03 High throughput screening for novel enzymes
US09/894,956 US20020015997A1 (en) 1997-06-16 2001-06-27 Capillary array-based sample screening
US09/975,036 US20030049841A1 (en) 1997-06-16 2001-10-10 High throughput or capillary-based screening for a bioactivity or biomolecule
US10/084,552 US7019827B2 (en) 1997-06-16 2002-02-25 GigaMatrix holding tray having through-hole wells
US10/095,907 US20020102598A1 (en) 1997-06-16 2002-03-11 Positioning system for moving a selected station of a holding plate to a predetermined location for interaction with a probe
US10/096,701 US20020150949A1 (en) 1997-06-16 2002-03-12 High throughput screening for novel enzymes
US10/145,281 US20030077677A1 (en) 1997-06-16 2002-05-13 High throughput screening for sequences of interest
US10/145,280 US20030077620A1 (en) 1997-06-16 2002-05-13 High throughput screening for sequences of interest
US10/145,314 US20030092022A1 (en) 1997-06-16 2002-05-13 High throughput screening for sequences of interest
US10/151,469 US20030219752A1 (en) 1995-12-07 2002-05-17 Novel antigen binding molecules for therapeutic, diagnostic, prophylactic, enzymatic, industrial, and agricultural applications, and methods for generating and screening thereof
US10/157,653 US6866824B2 (en) 1997-06-16 2002-05-28 Capillary array-based sample screening
US10/156,878 US20030096220A1 (en) 1997-06-16 2002-05-28 Capillary array-based sample screening
US10/232,869 US20030003500A1 (en) 1997-06-16 2002-08-30 Capillary array-based sample screening
US10/237,247 US20030083575A1 (en) 1997-06-16 2002-09-04 Capillary array-based sample screening
US10/237,246 US20030013115A1 (en) 1997-06-16 2002-09-04 Capillary array-based sample screening
US10/286,194 US20030054543A1 (en) 1997-06-16 2002-11-01 Device for moving a selected station of a holding plate to a predetermined location for interaction with a probe
US10/506,930 US20050118707A1 (en) 1997-06-16 2003-03-11 Positioning system for moving a selected station of a holding plate to a predetermined location for interaction with a probe
US10/626,477 US20050070005A1 (en) 1997-06-16 2003-07-23 High throughput or capillary-based screening for a bioactivity or biomolecule
US10/688,057 US20040241759A1 (en) 1997-06-16 2003-10-17 High throughput screening of libraries
US10/842,187 US20050069917A1 (en) 1997-06-16 2004-05-10 High throughput screening for novel enzymes
US10/948,807 US20050040550A1 (en) 1997-06-16 2004-09-23 High throughput screening for novel bioactivities
US10/960,137 US20050064498A1 (en) 1997-06-16 2004-10-07 High throughput screening for sequences of interest
US10/964,940 US20050046833A1 (en) 1997-06-16 2004-10-14 Gigamatrix holding tray having through-hole wells

Related Child Applications (4)

Application Number Title Priority Date Filing Date
PCT/US1997/012239 Continuation-In-Part WO1998001581A1 (en) 1996-07-09 1997-07-09 Method of dna shuffling with polynucleotides produced by blockingor interrupting a synthesis or amplification process
US09/098,206 Continuation-In-Part US6174673B1 (en) 1997-06-16 1998-06-16 High throughput screening for novel enzymes
US09/444,112 Continuation-In-Part US6972183B1 (en) 1997-06-16 1999-11-22 Capillary array-based enzyme screening
US10/151,469 Continuation-In-Part US20030219752A1 (en) 1995-12-07 2002-05-17 Novel antigen binding molecules for therapeutic, diagnostic, prophylactic, enzymatic, industrial, and agricultural applications, and methods for generating and screening thereof

Publications (1)

Publication Number Publication Date
US20030215798A1 true US20030215798A1 (en) 2003-11-20

Family

ID=25367333

Family Applications (9)

Application Number Title Priority Date Filing Date
US08/876,276 Abandoned US20030215798A1 (en) 1997-06-16 1997-06-16 High throughput fluorescence-based screening for novel enzymes
US09/098,206 Expired - Lifetime US6174673B1 (en) 1997-06-16 1998-06-16 High throughput screening for novel enzymes
US09/848,095 Expired - Lifetime US6872526B2 (en) 1997-06-16 2001-05-03 High throughput screening for novel Bioactivities
US09/848,083 Expired - Lifetime US6602675B2 (en) 1997-06-16 2001-05-03 High throughput screening of mycelia for bioactivities or biomolecules
US09/848,185 Abandoned US20020127560A1 (en) 1997-06-16 2001-05-03 High throughput screening for novel enzymes
US09/848,651 Expired - Lifetime US6806048B2 (en) 1997-06-16 2001-05-03 Method for high throughput screening of an environmental library
US10/096,701 Abandoned US20020150949A1 (en) 1997-06-16 2002-03-12 High throughput screening for novel enzymes
US10/842,187 Abandoned US20050069917A1 (en) 1997-06-16 2004-05-10 High throughput screening for novel enzymes
US10/948,807 Abandoned US20050040550A1 (en) 1997-06-16 2004-09-23 High throughput screening for novel bioactivities

Family Applications After (8)

Application Number Title Priority Date Filing Date
US09/098,206 Expired - Lifetime US6174673B1 (en) 1997-06-16 1998-06-16 High throughput screening for novel enzymes
US09/848,095 Expired - Lifetime US6872526B2 (en) 1997-06-16 2001-05-03 High throughput screening for novel Bioactivities
US09/848,083 Expired - Lifetime US6602675B2 (en) 1997-06-16 2001-05-03 High throughput screening of mycelia for bioactivities or biomolecules
US09/848,185 Abandoned US20020127560A1 (en) 1997-06-16 2001-05-03 High throughput screening for novel enzymes
US09/848,651 Expired - Lifetime US6806048B2 (en) 1997-06-16 2001-05-03 Method for high throughput screening of an environmental library
US10/096,701 Abandoned US20020150949A1 (en) 1997-06-16 2002-03-12 High throughput screening for novel enzymes
US10/842,187 Abandoned US20050069917A1 (en) 1997-06-16 2004-05-10 High throughput screening for novel enzymes
US10/948,807 Abandoned US20050040550A1 (en) 1997-06-16 2004-09-23 High throughput screening for novel bioactivities

Country Status (6)

Country Link
US (9) US20030215798A1 (en)
EP (1) EP1009858A4 (en)
JP (1) JP2002505590A (en)
AU (1) AU749587B2 (en)
CA (1) CA2294380A1 (en)
WO (1) WO1998058085A1 (en)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030165955A1 (en) * 2002-01-22 2003-09-04 Suich Daniel J. Fluorogenic dyes
US20060128033A1 (en) * 2003-01-21 2006-06-15 Chiron Corporation Fluorogenic dyes
US20060147937A1 (en) * 1999-11-23 2006-07-06 Chromocell Corporation Isolation of living cells and preparation of cell lines based on detection and quantification of preselected cellular ribonucleic acid sequences
US20090106853A1 (en) * 2004-02-18 2009-04-23 Kambiz Shekdar Methods and materials using signaling probes
WO2011017288A1 (en) 2009-08-05 2011-02-10 Chromocell Corporation Improved plants, microbes, and organisms
US8697383B2 (en) 2010-05-25 2014-04-15 Mitsubishi Rayon Co., Ltd. Fluorescent substrate for detection of enzymatic activity of nitrile-related enzyme
US8945848B2 (en) 2009-07-31 2015-02-03 Chromocell Corporation Methods and compositions for identifying and validating modulators of cell fate
US9051597B2 (en) 2010-05-25 2015-06-09 Mitsubishi Rayon Co., Ltd. Fluorescent substrate for detection of enzymatic activity of nitrile-related enzyme
WO2015200501A1 (en) * 2014-06-24 2015-12-30 The Scripps Research Institute Strain prioritization for natural product discovery by a high throughput real-time pcr method
US10227583B2 (en) 2016-12-12 2019-03-12 xCella Biosciences, Inc. Methods and systems for screening using microcapillary arrays

Families Citing this family (148)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6406855B1 (en) 1994-02-17 2002-06-18 Maxygen, Inc. Methods and compositions for polypeptide engineering
US6117679A (en) 1994-02-17 2000-09-12 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US6335160B1 (en) 1995-02-17 2002-01-01 Maxygen, Inc. Methods and compositions for polypeptide engineering
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US6995017B1 (en) 1994-02-17 2006-02-07 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US6165793A (en) * 1996-03-25 2000-12-26 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US6506602B1 (en) 1996-03-25 2003-01-14 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US20070009930A1 (en) * 1996-12-18 2007-01-11 Maxygen, Inc. Methods and compositions for polypeptide engineering
US6395547B1 (en) 1994-02-17 2002-05-28 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US6365408B1 (en) 1998-06-19 2002-04-02 Maxygen, Inc. Methods of evolving a polynucleotides by mutagenesis and recombination
US7883872B2 (en) * 1996-10-10 2011-02-08 Dyadic International (Usa), Inc. Construction of highly efficient cellulase compositions for enzymatic hydrolysis of cellulose
US5811381A (en) * 1996-10-10 1998-09-22 Mark A. Emalfarb Cellulase compositions and methods of use
US6326204B1 (en) 1997-01-17 2001-12-04 Maxygen, Inc. Evolution of whole cells and organisms by recursive sequence recombination
IL130635D0 (en) 1997-01-17 2000-06-01 Maxygen Inc Evolution of whole cells and organisms by recursive sequence recombination
US7148054B2 (en) 1997-01-17 2006-12-12 Maxygen, Inc. Evolution of whole cells and organisms by recursive sequence recombination
US6159688A (en) 1997-03-18 2000-12-12 Novo Nordisk A/S Methods of producing polynucleotide variants
US20030215798A1 (en) * 1997-06-16 2003-11-20 Diversa Corporation High throughput fluorescence-based screening for novel enzymes
US20040241759A1 (en) * 1997-06-16 2004-12-02 Eileen Tozer High throughput screening of libraries
WO2002031203A2 (en) * 2000-10-10 2002-04-18 Diversa Corporation High throughput or capillary-based screening for a bioactivity or biomolecule
US20050070005A1 (en) * 1997-06-16 2005-03-31 Martin Keller High throughput or capillary-based screening for a bioactivity or biomolecule
AU746786B2 (en) * 1997-12-08 2002-05-02 California Institute Of Technology Method for creating polynucleotide and polypeptide sequences
US6541011B2 (en) 1998-02-11 2003-04-01 Maxygen, Inc. Antigen library immunization
US7390619B1 (en) 1998-02-11 2008-06-24 Maxygen, Inc. Optimization of immunomodulatory properties of genetic vaccines
US6740497B2 (en) * 1998-03-06 2004-05-25 The Regents Of The University Of California Method and apparatus for detecting cancerous cells using molecules that change electrophoretic mobility
US6897031B1 (en) 1998-04-17 2005-05-24 Rigel Pharmaceuticals, Inc. Multiparameter FACS assays to detect alterations in exocytosis
US8334238B2 (en) 1998-04-17 2012-12-18 Rigel, Inc. Multiparameter FACS assays to detect alterations in cellular parameters and to screen small molecule libraries
DK1071809T3 (en) * 1998-04-17 2003-12-01 Rigel Pharmaceuticals Inc Multiparameter FACS test for the detection of alterations in cellular parameters
IL139093D0 (en) 1998-05-01 2001-11-25 Maxygen Inc Optimization of pest resistance genes using dna shuffling
JP2002522072A (en) 1998-08-12 2002-07-23 マキシジェン, インコーポレイテッド dna shuffling of the mono-oxygenase gene for the production of industrial chemicals.
US6461813B2 (en) 1998-09-21 2002-10-08 Rigel Pharmaceuticals, Inc. Multiparameter FACS assays to detect alterations in cell cycle regulation
US6500639B2 (en) 1998-10-07 2002-12-31 Maxygen, Inc. DNA shuffling to produce nucleic acids for mycotoxin detoxification
AU1619400A (en) 1998-11-10 2000-05-29 Maxygen, Inc. Modified adp-glucose pyrophosphorylase for improvement and optimization of plantphenotypes
US20020090612A1 (en) * 1999-01-08 2002-07-11 Jonathan M. Rothberg Method of identifying nucleic acids
IL137868D0 (en) 1999-01-19 2001-10-31 Maxygen Inc Oligonucleotide mediated nucleic acid recombination
US6376246B1 (en) 1999-02-05 2002-04-23 Maxygen, Inc. Oligonucleotide mediated nucleic acid recombination
IL144657D0 (en) 1999-02-11 2002-06-30 Maxygen Inc High throughput mass spectrometry
JP3399518B2 (en) * 1999-03-03 2003-04-21 インターナショナル・ビジネス・マシーンズ・コーポレーション Semiconductor structure and manufacturing method thereof
US6531316B1 (en) 1999-03-05 2003-03-11 Maxyag, Inc. Encryption of traits using split gene sequences and engineered genetic elements
CA2362737A1 (en) 1999-03-05 2000-09-08 Maxygen, Inc. Recombination of insertion modified nucleic acids
US7270969B2 (en) * 1999-05-05 2007-09-18 Phylogica Limited Methods of constructing and screening diverse expression libraries
AT320486T (en) * 1999-05-05 2006-04-15 Phylogica Ltd Isolation of biological modulators of bibiotheken with biodiverse gene fragments
US7803765B2 (en) * 1999-05-05 2010-09-28 Phylogica Limited Methods of constructing biodiverse gene fragment libraries and biological modulators isolated therefrom
US6436675B1 (en) 1999-09-28 2002-08-20 Maxygen, Inc. Use of codon-varied oligonucleotide synthesis for synthetic shuffling
US20040002474A1 (en) * 1999-10-07 2004-01-01 Maxygen Inc. IFN-alpha homologues
AU7646100A (en) * 1999-11-05 2001-05-14 Novozymes A/S A high throughput screening (hts) method
WO2001032829A2 (en) * 1999-11-05 2001-05-10 Novozymes A/S Methods to screen microorganisms or gene libraries for products secreted from a cell
US6686515B1 (en) 1999-11-23 2004-02-03 Maxygen, Inc. Homologous recombination in plants
US7115712B1 (en) * 1999-12-02 2006-10-03 Maxygen, Inc. Cytokine polypeptides
US20010039014A1 (en) * 2000-01-11 2001-11-08 Maxygen, Inc. Integrated systems and methods for diversity generation and screening
AU4193901A (en) * 2000-02-28 2001-09-12 Maxygen Inc Single-stranded nucleic acid template-mediated recombination and nucleic acid fragment isolation
US20010049104A1 (en) * 2000-03-24 2001-12-06 Stemmer Willem P.C. Methods for modulating cellular and organismal phenotypes
US20010047029A1 (en) * 2000-04-26 2001-11-29 Handelsman Jo E. Triaryl cation antibiotics from environmental DNA
US7074590B2 (en) * 2000-06-23 2006-07-11 Maxygen, Inc. Chimeric promoters
WO2002000717A2 (en) 2000-06-23 2002-01-03 Maxygen, Inc. Novel co-stimulatory molecules
US20020072097A1 (en) * 2000-07-07 2002-06-13 Delcardayre Stephen Molecular breeding of transposable elements
US6858422B2 (en) * 2000-07-13 2005-02-22 Codexis, Inc. Lipase genes
AU8499701A (en) * 2000-08-24 2002-03-04 Maxygen Inc Novel constructs and their use in metabolic pathway engineering
JP2007500514A (en) 2003-04-29 2007-01-18 イー.アイ. デュ ポン デ ヌムール アンド カンパニー Novel glyphosate n- acetyltransferase (gat) gene
WO2002070684A2 (en) * 2001-01-11 2002-09-12 Lion Bioscience Ag Gene library for screening methods
EP1385853A4 (en) * 2001-01-12 2005-02-16 Univ California Beta-lactamase substrates having phenolic ethers
US8008459B2 (en) * 2001-01-25 2011-08-30 Evolva Sa Concatemers of differentially expressed multiple genes
EP1472349B1 (en) * 2002-01-25 2008-10-29 Evolva AG Methods for multiple parameter screening and evolution of cells to produce small molecules with multiple functionalities
AT501251T (en) * 2001-01-25 2011-03-15 Evolva Ltd cell library
JP4194934B2 (en) * 2001-05-26 2008-12-10 ワン セル システムズ インコーポレイテッド Secretion method of protein by the encapsulated cells
WO2003012126A2 (en) * 2001-08-03 2003-02-13 Diversa Corporation Epoxide hydrolases, nucleic acids encoding them and methods for making and using them
US7647184B2 (en) * 2001-08-27 2010-01-12 Hanall Pharmaceuticals, Co. Ltd High throughput directed evolution by rational mutagenesis
DE10146572A1 (en) * 2001-09-21 2003-04-10 Basf Ag A method for preparing a normalized gene bank from nucleic acid extracts of soil samples and the use thereof
US7026111B2 (en) * 2001-10-15 2006-04-11 Beckman Coulter, Inc. Methods and reagents for improved cell-based assays
GB0125043D0 (en) * 2001-10-17 2001-12-12 Biotica Tech Ltd Production, detection and use of transformant cells
US20040137547A1 (en) * 2001-12-28 2004-07-15 Medtronic Minimed, Inc. Method for formulating a glucose oxidase enzyme with a desired property or properties and a glucose oxidase enzyme with the desired property
US20030224404A1 (en) * 2002-02-25 2003-12-04 Manuel Vega High throughput directed evolution of nucleic acids by rational mutagenesis
US20030166010A1 (en) * 2002-02-25 2003-09-04 Affholter Joseph A. Custom ligand design for biomolecular filtration and purification for bioseperation
AU2002248051A1 (en) * 2002-04-09 2003-12-19 Genofocus Co., Ltd. Stabilized biocatalysts and methods of bioconversion using the same
DK1529110T3 (en) * 2002-08-01 2012-01-30 Evolva Ltd A method of mixing large number of heterologous genes
CA2494798A1 (en) 2002-08-06 2005-01-13 Verdia, Inc. Ap1 amine oxidase variants
AT471981T (en) 2002-08-20 2010-07-15 B R A I N Biotechnology Res An Isolation and cloning of dna from uncultivated organisms
US20060020396A1 (en) * 2002-09-09 2006-01-26 Rene Gantier Rational directed protein evolution using two-dimensional rational mutagenesis scanning
US20050202438A1 (en) * 2002-09-09 2005-09-15 Rene Gantier Rational directed protein evolution using two-dimensional rational mutagenesis scanning
ES2343518T3 (en) * 2002-09-09 2010-08-03 Hanall Biopharma Co., Ltd. Interferon alfa polypeptide protease resistant they modified.
US20040091932A1 (en) * 2002-11-13 2004-05-13 Nutsibidze Nugzar N. Method for producing from microbial sources enzymes having multiple improved characteristics
DE602004015084D1 (en) * 2003-03-10 2008-08-28 Univ Johns Hopkins Method and apparatus for environmental monitoring and biological exploration
US7041481B2 (en) 2003-03-14 2006-05-09 The Regents Of The University Of California Chemical amplification based on fluid partitioning
USRE43365E1 (en) 2003-03-14 2012-05-08 Lawrence Livermore National Security, Llc Apparatus for chemical amplification based on fluid partitioning in an immiscible liquid
GB0307428D0 (en) 2003-03-31 2003-05-07 Medical Res Council Compartmentalised combinatorial chemistry
GB0307403D0 (en) 2003-03-31 2003-05-07 Medical Res Council Selection by compartmentalised screening
US20050221339A1 (en) * 2004-03-31 2005-10-06 Medical Research Council Harvard University Compartmentalised screening by microfluidic control
WO2004097027A2 (en) * 2003-04-25 2004-11-11 Dow Global Technologies Inc. Screening of biocatalysts in plants
CN108486086A (en) 2003-07-02 2018-09-04 维莱尼姆公司 Glucanases, nucleic acids encoding them and methods for making and using them
WO2005012550A2 (en) * 2003-07-31 2005-02-10 Diversa Corporation Screening methods and libraries of trace amounts of dna from uncultivated microorganisms
US20070017870A1 (en) 2003-09-30 2007-01-25 Belov Yuri P Multicapillary device for sample preparation
EP1677886A1 (en) * 2003-09-30 2006-07-12 Chromba, Inc. Multicapillary column for chromatography and sample preparation
AU2005250511B2 (en) * 2004-06-03 2012-01-19 Phylogica Limited Peptide modulators of cellular phenotype and bi-nucleic acid fragment library
EP1767621A4 (en) * 2004-06-08 2008-03-19 Toagosei Co Ltd Method of purifying environmental dna and method of efficiently screening protein-encoding gene from environmental dna
BRPI0510939A (en) 2004-06-16 2007-07-17 Diversa Corp Compositions and methods for enzymatic discoloration of chlorophyll
US20080070291A1 (en) * 2004-06-16 2008-03-20 David Lam Compositions and Methods for Enzymatic Decolorization of Chlorophyll
US7968287B2 (en) 2004-10-08 2011-06-28 Medical Research Council Harvard University In vitro evolution in microfluidic systems
US20060078893A1 (en) 2004-10-12 2006-04-13 Medical Research Council Compartmentalised combinatorial chemistry by microfluidic control
WO2006099207A2 (en) 2005-03-10 2006-09-21 Diversa Corporation Lyase enzymes, nucleic acids encoding them and methods for making and using them
MX300732B (en) 2005-03-15 2012-06-28 Verenium Corp Cellulases, nucleic acids encoding them and methods for making and using them.
PT2314623E (en) 2005-06-21 2012-10-02 Xoma Technology Ltd Il-1beta binding antibodies and fragments thereof
EP2363205A3 (en) 2006-01-11 2014-06-04 Raindance Technologies, Inc. Microfluidic Devices And Methods Of Use In The Formation And Control Of Nanoreactors
EP2444490B1 (en) 2006-02-10 2014-02-12 Verenium Corporation Cellulolytic enzymes, nucleic acids encoding them and methods for making and using them
USRE45660E1 (en) 2006-02-14 2015-09-01 Bp Corporation North America Inc. Xylanases, nucleic acids encoding them and methods for making and using them
EP1987178B1 (en) 2006-02-20 2015-03-25 Phylogica Limited Method of constructing and screening libraries of peptide structures
CN101437954B (en) 2006-03-07 2015-09-09 嘉吉公司 Aldolase and nucleic acids encoding the aldolase and their preparation and use
BR122017003017B1 (en) 2006-03-07 2018-10-23 Basf Enzymes Llc nucleic acid, expression cassette, vector, cloning vehicle transgenic organism, polypeptide, signal peptide, composition, and methods for producing a recombinant polypeptide, to generate a variant of a nucleic acid to cleave a carbon-carbon bond in a composition to form a carbon-carbon bond, to a foodstuff, an animal feed or drink, and to convert a biomass or any lignocellulosic material in a fuel
US9580760B2 (en) * 2006-03-28 2017-02-28 Becton, Dickinson And Company Rapid detection of mold by accelerated growth and detection
US9562837B2 (en) 2006-05-11 2017-02-07 Raindance Technologies, Inc. Systems for handling microfludic droplets
US20080014589A1 (en) 2006-05-11 2008-01-17 Link Darren R Microfluidic devices and methods of use thereof
CA2669453C (en) 2006-08-04 2018-11-13 Verenium Corporation Glucanases, nucleic acids encoding them and methods for making and using them
WO2008021123A1 (en) 2006-08-07 2008-02-21 President And Fellows Of Harvard College Fluorocarbon emulsion stabilizing surfactants
WO2008034161A1 (en) * 2006-09-19 2008-03-27 Phylogica Limited Neuroprotective peptide inhibitors of ap-1 signaling and uses therefor
US7807454B2 (en) 2006-10-18 2010-10-05 The Regents Of The University Of California Microfluidic magnetophoretic device and methods for using the same
WO2008073914A2 (en) 2006-12-10 2008-06-19 Dyadic International Inc. Expression and high-throughput screening of complex expressed dna libraries in filamentous fungi
US9862956B2 (en) 2006-12-10 2018-01-09 Danisco Us Inc. Expression and high-throughput screening of complex expressed DNA libraries in filamentous fungi
MX2009008129A (en) * 2007-01-30 2010-03-17 Verenium Corp Enzymes for the treatment of lignocellulosics, nucleic acids encoding them and methods for making and using them.
WO2008097559A2 (en) 2007-02-06 2008-08-14 Brandeis University Manipulation of fluids and reactions in microfluidic systems
WO2008130623A1 (en) 2007-04-19 2008-10-30 Brandeis University Manipulation of fluids, fluid components and reactions in microfluidic systems
WO2008147530A1 (en) * 2007-05-24 2008-12-04 The Regents Of The University Of California Integrated fluidics devices with magnetic sorting
US8822409B2 (en) * 2007-06-20 2014-09-02 Phylogica Limited Compositions and uses thereof for the treatment of acute respiratory distress syndrome (ARDS) and clinical disorders associated with therewith
CA2736661A1 (en) * 2007-09-07 2009-03-12 Dyadic International, Inc. Novel fungal enzymes
CN101952437B (en) 2007-10-03 2014-04-09 维莱尼姆公司 Xylanases, nucleic acids encoding them and methods for making and using them
CA2710683A1 (en) 2008-01-03 2009-07-16 Verenium Corporation Transferases and oxidoreductases, nucleic acids encoding them and methods for making and using them
EP2274098B1 (en) * 2008-03-28 2013-12-25 Biotix, Inc. Multicapillary sample preparation devices and methods for processing analytes
EP2411148B1 (en) 2009-03-23 2018-02-21 Raindance Technologies, Inc. Manipulation of microfluidic droplets
EP2440941B1 (en) * 2009-06-10 2017-05-31 Cynvenio Biosystems, Inc. Sheath flow devices and methods
US8338182B2 (en) * 2010-02-08 2012-12-25 Arizona Board of Regents, a body corporate acting for and on behalf of Arizona State University Methods and systems for fluid examination and remediation
EP3392349A1 (en) 2010-02-12 2018-10-24 Raindance Technologies, Inc. Digital analyte analysis
US10351905B2 (en) 2010-02-12 2019-07-16 Bio-Rad Laboratories, Inc. Digital analyte analysis
US9399797B2 (en) 2010-02-12 2016-07-26 Raindance Technologies, Inc. Digital analyte analysis
US9366632B2 (en) 2010-02-12 2016-06-14 Raindance Technologies, Inc. Digital analyte analysis
WO2011140270A2 (en) 2010-05-05 2011-11-10 Arizona Board Of Regents For And On Behalf Of Arizona State University Methods and systems for ultra-trace analysis of liquids
US8993837B2 (en) 2010-08-13 2015-03-31 Pioneer Hi-Bred International, Inc Chimeric promoters and methods of use
EP2622103B1 (en) 2010-09-30 2018-09-12 Raindance Technologies, Inc. Sandwich assays in droplets
US9364803B2 (en) 2011-02-11 2016-06-14 Raindance Technologies, Inc. Methods for forming mixed droplets
US9150852B2 (en) 2011-02-18 2015-10-06 Raindance Technologies, Inc. Compositions and methods for molecular labeling
US8841071B2 (en) 2011-06-02 2014-09-23 Raindance Technologies, Inc. Sample multiplexing
US8658430B2 (en) 2011-07-20 2014-02-25 Raindance Technologies, Inc. Manipulating droplet size
EP2809783A2 (en) * 2012-02-02 2014-12-10 Invenra, Inc. High throughput screen for biologically active polypeptides
CA2872096A1 (en) 2012-05-04 2013-11-07 E. I. Du Pont De Nemours And Company Compositions and methods comprising sequences having meganuclease activity
CA2905595A1 (en) 2013-03-14 2014-09-25 Pioneer Hi-Bred International, Inc. Compositions having dicamba decarboxylase activity and methods of use
EP2970935A1 (en) 2013-03-14 2016-01-20 Pioneer Hi-Bred International, Inc. Compositions having dicamba decarboxylase activity and methods of use
AU2014318731A1 (en) * 2013-09-11 2016-03-17 Agenus Inc. High throughput screening for biomolecules
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
CN107810277A (en) 2015-04-21 2018-03-16 通用自动化实验技术公司 High resolution systems, kits, apparatus, and methods for high throughput microbiology applications
US9988624B2 (en) 2015-12-07 2018-06-05 Zymergen Inc. Microbial strain improvement by a HTP genomic engineering platform
EP3321352A1 (en) * 2016-11-09 2018-05-16 Biomillenia SAS Auxotrophic selection system
WO2018138271A1 (en) * 2017-01-26 2018-08-02 Biomillenia Sas High-throughput microfluidic screening in droplets

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5055390A (en) * 1988-04-22 1991-10-08 Massachusetts Institute Of Technology Process for chemical manipulation of non-aqueous surrounded microdroplets
US5783431A (en) * 1996-04-24 1998-07-21 Chromaxome Corporation Methods for generating and screening novel metabolic pathways

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4643968A (en) 1981-01-29 1987-02-17 Massachusetts Institute Of Technology Process for determining metabolism and growth of cells under various conditions
US4399219A (en) 1981-01-29 1983-08-16 Massachusetts Institute Of Technology Process for isolating microbiologically active material
SE441009B (en) 1982-03-08 1985-09-02 Kjell Nilsson Seen immobilizing living biomaterial polymers perlformiga
US4801529A (en) * 1985-06-18 1989-01-31 Brandeis University Methods for isolating mutant microoganisms using microcapsules coated with indicator material
US4916060A (en) 1985-09-17 1990-04-10 Massachusetts Institute Of Technology Process for chemical measurement in small volume samples by fluorescent indicators
US4959301A (en) 1988-04-22 1990-09-25 Massachusetts Institute Of Technology Process for rapidly enumerating viable entities
US5225332A (en) 1988-04-22 1993-07-06 Massachusetts Institute Of Technology Process for manipulation of non-aqueous surrounded microdroplets
JP3537141B2 (en) * 1992-10-30 2004-06-14 ザ ゼネラル ホスピタル コーポレーション Ho捉 system using interaction for new protein separation
US6117679A (en) * 1994-02-17 2000-09-12 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US5525490A (en) * 1994-03-29 1996-06-11 Onyx Pharmaceuticals, Inc. Reverse two-hybrid method
US5663046A (en) * 1994-06-22 1997-09-02 Pharmacopeia, Inc. Synthesis of combinatorial libraries
US5824485A (en) * 1995-04-24 1998-10-20 Chromaxome Corporation Methods for generating and screening novel metabolic pathways
US5958672A (en) * 1995-07-18 1999-09-28 Diversa Corporation Protein activity screening of clones having DNA from uncultivated microorganisms
US6057103A (en) * 1995-07-18 2000-05-02 Diversa Corporation Screening for novel bioactivities
US5968738A (en) * 1995-12-06 1999-10-19 The Board Of Trustees Of The Leland Stanford Junior University Two-reporter FACS analysis of mammalian cells using green fluorescent proteins
CA2239686A1 (en) * 1995-12-07 1997-06-12 Recombinant Biocatalysis, Inc. Method of screening for enzyme activity
US6803188B1 (en) * 1996-01-31 2004-10-12 The Regents Of The University Of California Tandem fluorescent protein constructs
US5763239A (en) * 1996-06-18 1998-06-09 Diversa Corporation Production and use of normalized DNA libraries
WO1998041869A1 (en) * 1997-03-18 1998-09-24 Chromaxome Corporation Methods for screening compounds using encapsulated cells
US5858367A (en) * 1997-03-27 1999-01-12 Case Western Reserve University Methods for screening for antimicrobials utilizing AarC and compositions thereof
US6969584B2 (en) 1997-06-12 2005-11-29 Rigel Pharmaceuticals, Inc. Combinatorial enzymatic complexes
US20030215798A1 (en) * 1997-06-16 2003-11-20 Diversa Corporation High throughput fluorescence-based screening for novel enzymes
US6455263B2 (en) 1998-03-24 2002-09-24 Rigel Pharmaceuticals, Inc. Small molecule library screening using FACS
DK1071809T3 (en) 1998-04-17 2003-12-01 Rigel Pharmaceuticals Inc Multiparameter FACS test for the detection of alterations in cellular parameters
US6391576B1 (en) * 1999-10-13 2002-05-21 Japan Bioindustry Association Method for isolating a microbe

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5055390A (en) * 1988-04-22 1991-10-08 Massachusetts Institute Of Technology Process for chemical manipulation of non-aqueous surrounded microdroplets
US5783431A (en) * 1996-04-24 1998-07-21 Chromaxome Corporation Methods for generating and screening novel metabolic pathways

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100212040A1 (en) * 1999-11-23 2010-08-19 Chromocell Corporation Isolation of living cells and preparation of cell lines based on detection and quantification of preselected cellular ribonucleic acid sequences
US20060147937A1 (en) * 1999-11-23 2006-07-06 Chromocell Corporation Isolation of living cells and preparation of cell lines based on detection and quantification of preselected cellular ribonucleic acid sequences
US7026166B2 (en) * 2002-01-22 2006-04-11 Chiron Corporation Fluorogenic dyes
US20030165955A1 (en) * 2002-01-22 2003-09-04 Suich Daniel J. Fluorogenic dyes
US20060128033A1 (en) * 2003-01-21 2006-06-15 Chiron Corporation Fluorogenic dyes
US7704756B2 (en) 2003-01-21 2010-04-27 Novartis Vaccines And Diagnostics, Inc. Fluorogenic dyes
US20090106853A1 (en) * 2004-02-18 2009-04-23 Kambiz Shekdar Methods and materials using signaling probes
US8916503B2 (en) * 2004-02-18 2014-12-23 Chromocell Corporation Methods and materials using signaling probes
US8945848B2 (en) 2009-07-31 2015-02-03 Chromocell Corporation Methods and compositions for identifying and validating modulators of cell fate
US9657357B2 (en) 2009-07-31 2017-05-23 Chromocell Corporation Methods and compositions for identifying and validating modulators of cell fate
WO2011017288A1 (en) 2009-08-05 2011-02-10 Chromocell Corporation Improved plants, microbes, and organisms
US9051597B2 (en) 2010-05-25 2015-06-09 Mitsubishi Rayon Co., Ltd. Fluorescent substrate for detection of enzymatic activity of nitrile-related enzyme
US8697383B2 (en) 2010-05-25 2014-04-15 Mitsubishi Rayon Co., Ltd. Fluorescent substrate for detection of enzymatic activity of nitrile-related enzyme
WO2015200501A1 (en) * 2014-06-24 2015-12-30 The Scripps Research Institute Strain prioritization for natural product discovery by a high throughput real-time pcr method
US10227583B2 (en) 2016-12-12 2019-03-12 xCella Biosciences, Inc. Methods and systems for screening using microcapillary arrays

Also Published As

Publication number Publication date
US20050069917A1 (en) 2005-03-31
US6602675B2 (en) 2003-08-05
US20020150949A1 (en) 2002-10-17
WO1998058085A1 (en) 1998-12-23
EP1009858A1 (en) 2000-06-21
US20050040550A1 (en) 2005-02-24
AU749587B2 (en) 2002-06-27
JP2002505590A (en) 2002-02-19
US20010034031A1 (en) 2001-10-25
US20010034040A1 (en) 2001-10-25
US20020001809A1 (en) 2002-01-03
US20020127560A1 (en) 2002-09-12
US6806048B2 (en) 2004-10-19
EP1009858A4 (en) 2001-03-07
US6872526B2 (en) 2005-03-29
AU8150298A (en) 1999-01-04
CA2294380A1 (en) 1998-12-23
US6174673B1 (en) 2001-01-16

Similar Documents

Publication Publication Date Title
Schaerli et al. The potential of microfluidic water-in-oil droplets in experimental biology
O'Sullivan Methods for analysis of the intestinal microflora
US6479652B1 (en) Oligonucleotide mediated nucleic acid recombination
EP1007654B1 (en) In vitro peptide or protein expression library
US5981235A (en) Methods for isolating nucleic acids using alkaline protease
EP2341151B1 (en) Methods for determining sequence variants using ultra-deep sequencing
US9139637B2 (en) Yeast cell surface display of proteins and uses thereof
Reetz et al. Superior biocatalysts by directed evolution
Minshull et al. Protein evolution by molecular breeding
US5962764A (en) Functional characterization of genes
US6423538B1 (en) Yeast cell surface display of proteins and uses thereof
EP2253704A1 (en) Oligonucleotide mediated nucleic acid recombination
US6897023B2 (en) Method for determining relative abundance of nucleic acid sequences
McKILLIP et al. Real-time nucleic acid–based detection methods for pathogenic bacteria in food
Daugherty et al. Flow cytometric screening of cell-based libraries
EP2385133A2 (en) Yeast cell surface display of proteins and uses thereof
US7462469B2 (en) Integrated system for diversity generation and screening
US7229765B2 (en) Random-primed reverse transcriptase-in vitro transcription method for RNA amplification
US9957549B2 (en) Compositions and methods for negative selection of non-desired nucleic acid sequences
Daniel The soil metagenome–a rich resource for the discovery of novel natural products
Ishii et al. Single-cell analysis and isolation for microbiology and biotechnology: methods and applications
JP4227196B2 (en) Preparation and use of averaging dna library
Lorenz et al. Screening for novel enzymes for biocatalytic processes: accessing the metagenome as a resource of novel functional sequence space
EP2408927B1 (en) Probe compound for detecting and isolating enzymes and means and methods using the same
EP0674650B1 (en) Nucleic acid probes for lactobacillus detection

Legal Events

Date Code Title Description
AS Assignment

Owner name: DIVERSA CORPORATION, CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SHORT, JAY M.;KELLER, MARTIN;REEL/FRAME:010476/0273;SIGNING DATES FROM 19991201 TO 19991207

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION